UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended March 31, ~~2025~~2026

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 000-55000

EARTH SCIENCE TECH, INC.

(Exact name of registrant as specified in its charter)

florida		45-4267181
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

8950 SW 74^th CT

Suite 1401

Miami, FL 33156, USA

(Address of principal executive offices, zip code)

(305) 724-5684

(Registrant’s telephone number, including area code)

8950 SW 74th CT

Suite 101

Miami, FL 33156, USA

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(g) of the Act:

Title of Each Class		Trading Symbol		Name of each exchange on which registered
Common Stock $0.001 par value		ETST		Over the Counter Bulletin Board

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☒ No ☐

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large, accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large, accelerated filer	☐		Accelerated filer	☐

Non-accelerated filer	☐	(Do not check if a smaller reporting company)	Smaller reporting company	☒

Emerging Growth Company	☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☒

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the Registrant’s most recently completed fiscal year (March 31, ~~2025~~2026) was approximately $3613,~~918~~576,~~487~~582.88

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

Yes ☐ No ☒

The number of shares of Common Stock, $0.001 par value, outstanding on June ~~11th~~17, ~~2025~~2026, was ~~294~~288,~~297~~174,~~607~~215.

APPLICABLE ONLY TO CORPORATE ISSUERS

Audit Firm ID	Auditor Name	Auditor Location
3523	Stephano Slack, LLC.	Wayne, PA
178	Semple, Marchal & Cooper, LLP	Phoenix, AZ

TABLE OF CONTENTS

		PAGE
PART I
Item 1.	Business.	4
Item 1A.	Risk Factors.	79
Item 1B.	Unresolved Staff Comments.	1415
Item 1C.	Cybersecurity.	1416
Item 2.	Properties.	1416
Item 3.	Legal Proceedings.	1416
Item 4.	Mine Safety Disclosure.	1416
PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.	1516
Item 6.	Selected Financial Data	1719
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	1719
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk.	2325
Item 8.	Financial Statements and Supplementary Data.	2325
Item 9A.	Controls and Procedures.	2527
Item 9B.	Other Information.	2627
PART III
Item 10.	Directors, Executive Officers and Corporate Governance.	2628
Item 11.	Executive Compensation.	2930
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.	3032
Item 13.	Certain Relationships and Related Transactions, and Director Independence.	3335
Item 14.	Principal Accounting Fees and Services.	3435
PART IV
Item 15.	Exhibits, Financial Statement Schedules.	3536
Item 16.	FORM 10-K Summary	3536
	SIGNATURES	3637

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly, and current reports, proxy statements and other information required by the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with the Securities and Exchange Commission (the “SEC”). You may read and copy any document we file with the SEC at the SEC’s public reference room located at 100 F Street, N.E., Washington, D.C. 20549, U.S.A. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Our SEC filings are also available to the public from the SEC’s internet site at http://www.sec.gov.

On our Internet website, http://www.earthsciencetech.com, we post the following recent filings as soon as reasonably practicable after they are electronically filed with or furnished to the SEC: our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act.

When we use the terms “ETST,” “Company,” “we,” “our,” and “us,” we mean Earth Science Tech, Inc., a Florida corporation, and its consolidated subsidiaries, taken as a whole, as well as any predecessor entities, unless the context indicates otherwise.

FORWARD LOOKING STATEMENTS

This Annual Report on Form 10-K, the other reports, statements, and information that the Company has previously filed with or furnished to, or that we may subsequently file with or furnish to, the SEC, and public announcements that we have previously made or may subsequently make include, may include, or may incorporate by reference certain statements that may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and that are intended to enjoy the protection of the safe harbor for forward-looking statements provided by that Act. To the extent that any statement made in this report contains information that is not historical, these statements are essentially forward-looking. Forward-looking statements can be identified using words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, marketability of our products; legal and regulatory risks associated with OTC Markets; our ability to raise additional capital to finance our activities; the future trading of our common stock; our ability to operate as a public company; our ability to protect our proprietary information; general economic and business conditions; the volatility of our operating results and financial condition; our ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed from time to time in our filings with the SEC, or otherwise.

Information regarding market and industry statistics contained in this report is included based on information available to us that we believe is accurate. It is generally based on industry and other publications that are not produced for the purposes of securities offerings or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompany any estimates of future market size, revenue and market acceptance of products and services. We do not undertake any obligation to publicly update any forward-looking statements. As a result, investors should not place undue reliance on these forward-looking statements.

PART I

ITEM 1. BUSINESS

BUSINESS BACKGROUND AND OVERVIEW

Earth Science Tech, Inc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010, and subsequently redomiciled to the State of Florida on June 27, 2022~~. As of November 8~~, ~~2022,~~headquartered ~~ETST~~in ~~operates as a strategic holding company~~Miami, ~~focused on value creation through the acquisition, operational optimization, and management of its operating businesses~~Florida. The Company’s current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: RxCompoundStore.com, LLC (“RxCompound”), Peaks Curative, LLC (“Peaks”), Avenvi, LLC (“Avenvi”), Mister Meds, LLC (“Mister Meds”), and Earth Science Foundation, Inc. (“ESF”). Subsequent to the reporting period, the Company acquired 100% of Las Villas Health Care, Inc. (“Villas”), DOConsultations, LLC (“DOC”), and an 80% interest in MagneChef (“Magne”).

~~RxCompound,~~ETST ~~based~~operates inas ~~Miami, Florida, is~~ a ~~fully~~diversified ~~licensed~~holding ~~compounding~~company ~~pharmacy~~focused ~~authorized~~on tothe ~~fulfill~~health ~~prescriptions~~and inwellness ~~the~~sector. ~~following~~The ~~states~~Company’s ~~and~~principal ~~territories:~~operating strategy ~~Arizona,~~is ~~Colorado,~~to ~~Delaware,~~build ~~Florida,~~a ~~Georgia,~~vertically ~~Illinois,~~integrated ~~Indiana,~~healthcare ~~Iowa,~~platform ~~Maine,~~that ~~Maryland,~~combines ~~Minnesota,~~compounding ~~Missouri,~~pharmacy ~~Nevada~~operations, ~~New~~telemedicine ~~Jersey~~platforms, ~~New~~clinical ~~York~~support, ~~North~~and ~~Carolina,~~patient ~~Ohio,~~fulfillment. ~~Oklahoma,~~The ~~Pennsylvania,~~Company’s ~~Rhode~~healthcare ~~Island,~~operations ~~Utah,~~are ~~Wisconsin~~supported ~~and~~by ~~Puerto~~investments ~~Rico.~~in ~~RxCompound~~real isestate ~~actively~~and asset ~~pursuing~~management ~~licensure in~~activities ~~the~~and ~~remaining~~a ~~U.S.~~consumer ~~states~~products business.

~~Peaks~~The iscore aof ~~telemedicine~~the ~~referral~~Company’s ~~platform~~value ~~offering~~proposition ~~asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds. The platform operates in states where either pharmacy~~ is ~~licensed. Through~~ the ~~development~~seamless integration of ~~its~~patient ~~own healthcare provider network~~care, ~~MyOnlineConsultation.com,~~from ~~and~~consultation ~~ongoing licensure expansion for both pharmacies, Peaks aims~~ to ~~offer services nationwide~~fulfillment. InThis ~~addition,~~is ~~the~~achieved ~~company~~through ~~has~~the ~~recently~~synergy ~~expanded~~of ~~into~~specialized ~~the~~subsidiaries. ~~veterinary~~The ~~market~~Company’s ~~through~~primary ~~the~~operating ~~acquisition~~businesses ~~of Zoolzy.com.~~include:

Avenvi is a diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company’s ongoing $5 million share repurchase program.

Business / Entity		Description
RxCompoundStore.com, LLC (“RxCompound”)		Miami-based licensed compounding pharmacy providing sterile and non-sterile medications in multiple U.S. states and Puerto Rico.

Mister Meds, LLC (“MisterMeds”)		Abilene, Texas compounding pharmacy that received full compounding licensure in March 2025; includes sterile compounding capabilities and hazardous drug handling.

Peaks Curative LLC(“Peaks”)		Telemedicine referral platform offering asynchronous consultations for compounded medications prepared by RxCompound and Mister Meds.

DOConsultation.com LLC (“DOC”)		Telehealth brand focused on home-based therapies and virtual consultations, with prescriptions fulfilled by the Company’s pharmacies.

Las Villas Health Care (“Villas”)		Brick-and-mortar healthcare facility designed to expand patient access.

Avenvi LLC		Real estate and asset management arm; supports healthcare infrastructure and manages the Company’s share repurchase program.

MagneChef		80%-owned direct-to-consumer kitchen products brand using proprietary intellectual property.

Mister Meds, acquired on October 1, 2024, is in Abilene, Texas. The pharmacy received full compounding licensure in March 2025. It operates out of a 5,000 sq. ft. facility owned by Avenvi and includes advanced sterile compounding capabilities with both positive and negative pressure environments, as well as hazardous drug handling. Mister Meds is currently applying for licensure in states not yet serviced by RxCompound.

ESF, a 501(c)(3) nonprofit organization incorporated on February 11, 2019, is the charitable arm of ETST. ESF accepts grants and donations to assist individuals who need financial support for prescription costs at both RxCompound and Mister Meds.

Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Our expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. We combine compassionate, personalized care with clear, trustworthy education—empowering you to take control of your health with confidence.

DOC was born with a passion to modernize the availability and delivery of home therapies. DOConsultations providers tailor a medication plan around your health and wellness goals and follow up with our patients to ensure results, while our partner pharmacies conveniently ship directly to your door.

MagneChef is a direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property.

Current Operations

CORPORATE STRATEGY

The company is a holding company focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The Company’s areas of focus include pharmaceutical compounding, telemedicine, real estate development, and direct to consumer products.

The Company’s strategic approach centers on resource integration across its subsidiaries to create operational efficiencies. Through its subsidiaries RxCompound and Mister Meds, the Company operates licensed compounding pharmacies offering both sterile and non-sterile preparations. These services are supported by Peaks and DOC, which facilitate asynchronous telemedicine consultations and prescription generation across the Company’s operating footprint. As of the date of this filing, the Company is pursuing additional licensure to expand pharmacy and telehealth operations nationwide.

InAs ~~parallel,~~of the ~~Company~~date isof ~~engaged~~this infiling, the ~~development~~Company ~~and~~has ~~management~~aggressively ofexpanded ~~real~~its ~~estate~~state ~~assets~~licensure, ~~through~~allowing ~~Avenvi.~~its ~~Avenvi’s~~pharmacy ~~operations~~and ~~provide infrastructure~~telehealth ~~support~~ services to ~~ETST’s~~reach ~~pharmacies~~a ~~and facilitate real estate~~near-~~related~~national ~~and other investment strategies, including the management of the Company’s share repurchase program~~footprint. ~~Additionally, Avenvi provides turnkey development and financing solutions to property buyers.~~

~~The~~Strategic ~~Company~~Asset ~~continues~~Management to& diversify its holdings through strategic acquisitions. During the reporting period and subsequent thereto, the Company acquired 100% of Villas, which provides specialized wellness services including sexual health treatments tailored to the Spanish-speaking market, and 80% of Magne, a consumer brand focused on patented direct-to-consumer products. These acquisitions are intended to diversify ETST’s presence in targeted demographic and product segments.Infrastructure

~~The~~Avenvi serves as the Company’s ~~nonprofit~~real ~~subsidiary,~~estate ~~Earth~~and ~~Science~~asset ~~Foundation,~~management ~~Inc~~arm. ~~(“ESF”),~~Avenvi ~~supports~~provides ~~access~~the tocritical ~~prescription~~physical ~~medications~~infrastructure required for ~~through~~the ~~donation~~Company’s expanding pharmacy operations and manages ETST’s real estate-~~based~~related ~~programs~~investment ~~that~~strategies. ~~help~~Additionally, ~~subsidize~~Avenvi plays ~~prescription~~a ~~costs~~pivotal ~~for~~role ~~qualifying~~in ~~patients~~the Company’s disciplined capital allocation strategy, which focuses on non-dilutive growth and the management of the Company’s share repurchase initiatives.

Diversified Holdings & Innovation

The Company maintains a 80% stake in MagneChef, a direct-to-consumer brand that leverages proprietary intellectual property to market innovative kitchen products. This subsidiary provides a diversified revenue stream and demonstrates the Company’s ability to commercialize unique IP across different consumer segments.

Capital Structure & Governance Focus

A defining pillar of the Company’s current strategy is fiscal discipline and shareholder alignment. Since the final share issuance in October 2023, management has focused exclusively on non-dilutive financing, significant reductions in authorized common stock (from 750 million to 300 million), and a robust share buyback program. This strategy is underpinned by a high level of insider ownership, with management holding approximately 48% of outstanding shares, the vast majority of which were purchased.

PRODUCT REGULATION

The Company’s operations are subject to extensive federal, state, and local laws and regulations governing the compounding, distribution, and delivery of pharmaceutical products, as well as the provision of telemedicine services and sale of consumer goods.

Pharmacy Regulation

~~RxCompound~~Our pharmacy subsidiaries, RxCompound and Mister Meds ~~operate~~are asprimarily ~~licensed~~governed ~~compounding~~by ~~pharmacies~~Section ~~and~~503A ~~are~~of ~~regulated~~the byFederal ~~the~~Food, ~~state~~Drug, ~~boards~~and ofCosmetic ~~pharmacy~~Act (FDCA). inUnlike ~~each~~large-scale ~~jurisdiction~~manufacturers, ~~in which~~our ~~they~~compounding pharmacies are ~~authorized~~regulated topredominantly ~~dispense~~by ~~medications.~~individual ~~These~~State ~~pharmacies~~Boards ~~are~~of ~~also~~Pharmacy. We ~~subject~~maintain tostrict ~~applicable~~adherence ~~provisions~~to ofUnited ~~the~~States ~~Federal~~Pharmacopeia ~~Food,~~(USP) ~~Drug~~standards, ~~and~~ ~~Cosmetic~~specifically ~~Act,~~USP ~~including~~<795> ~~those~~for ~~governing~~non-sterile ~~drug~~preparations and ~~compounding~~USP as<797> ~~outlined~~for insterile ~~Sections 503A~~preparations. ~~The~~These ~~pharmacies~~standards ~~compound~~dictate ~~both~~the ~~sterile~~environmental controls, rigorous testing protocols, and ~~non-sterile~~quality ~~medications~~assurance inmeasures ~~accordance~~necessary ~~with~~to ensure the ~~United~~integrity ~~States~~and ~~Pharmacopeia~~potency ~~(USP)~~of ~~chapters~~customized ~~<795>,~~medications ~~<797>,~~dispensed ~~and~~upon ~~<800>,~~receipt ~~where~~of ~~applicable.~~patient-specific ~~Additional~~prescriptions. ~~oversight~~As ~~may~~we ~~include~~expand ~~inspections~~our bygeographical ~~state~~footprint, ~~regulatory~~we ~~authorities~~continuously ~~and~~monitor ~~compliance~~state-level ~~with~~licensure ~~the~~requirements ~~Drug~~to ~~Enforcement~~ensure ~~Administration~~compliant ~~(DEA)~~dispensing ~~for~~across ~~handling~~all ~~controlled~~active ~~substances, where applicable~~jurisdictions.

Telemedicine Regulation

The Company’s digital health operations, facilitated through Peaks, ~~Las~~ ~~Villas~~DOC and ~~DOConsultations~~our ~~operate~~integrated aspharmacy ~~telemedicine~~ platforms, ~~facilitating~~navigate ~~synchronous~~a multifaceted landscape of federal and ~~asynchronous~~state ~~consultations~~laws. ~~between~~We ~~patients~~currently operate under the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities, ~~and~~which ~~licensed~~permits our affiliated healthcare providers. ~~These~~to ~~services~~prescribe ~~are~~Schedule ~~governed~~II-V bycontrolled ~~applicable~~substances ~~state~~via ~~telehealth~~telemedicine ~~laws~~through December 31, ~~including~~2026, ~~licensure~~without ~~requirements for~~a ~~providers,~~prior ~~prescribing~~in-person ~~regulations~~evaluation. Furthermore, ~~patient~~our ~~consent~~business ~~protocols,~~structures ~~and~~are ~~electronic~~meticulously ~~privacy~~designed ~~and~~to ~~security~~comply ~~mandates~~with ~~under~~state Corporate Practice of Medicine (CPOM) doctrines, maintaining a clear separation between the ~~Health~~Company’s ~~Insurance Portability~~administrative support and ~~Accountability~~the ~~Act~~independent clinical ~~(HIPAA)~~judgment of licensed professionals. ~~The~~We ~~Company~~also ~~actively~~maintain ~~monitors~~comprehensive ~~state-level~~data ~~regulatory~~security ~~developments~~protocols to ensure ~~continued~~all ~~compliance~~patient interactions asand itrecords ~~expands~~remain ~~its~~compliant ~~network~~with ofthe ~~providers~~Health Insurance Portability and ~~service~~Accountability ~~coverage~~Act (HIPAA).

~~Nonprofit~~Specialized ~~Prescription~~Clinical ~~Assistance~~Services and Wellness

~~Earth~~Villas ~~Science~~represents ~~Foundation~~the Company’s commitment to personalized, ~~Inc~~in-person clinical care. This ~~(ESF)~~subsidiary ~~operates~~is assubject ato ~~501(c)(3)~~state-specific ~~nonprofit~~clinical ~~organization~~licensure and ~~complies~~must ~~with~~meet ~~IRS~~the ~~guidelines~~stringent standards set by regional Departments of Health for ~~charitable~~physical ~~entities~~wellness facilities. ~~ESF~~ ~~provides~~In ~~financial~~addition ~~assistance~~to ~~for~~medical ~~prescriptions~~board ~~filled~~oversight, atVillas adheres to Occupational Safety and Health Administration (OSHA) standards regarding the ~~Company’s~~management ~~affiliated~~of ~~pharmacies,~~clinical environments and ~~such~~the ~~assistance~~handling isof ~~provided~~medical waste. To ensure equitable access and ininformed ~~accordance~~consent, ~~with~~the ~~applicable~~facility ~~anti~~maintains rigorous language-~~kickback~~access protocols, ensuring all clinical documentation and ~~charitable~~patient ~~contribution~~disclosures meet ~~regulations~~federal standards for accuracy and cultural competence.

Asset Management and Capital Allocation

Avenvi serves as the strategic infrastructure and asset management arm of the Company, providing the logistical foundation for our pharmacy operations while overseeing critical financial initiatives. In its capacity managing the Company’s $10 million share repurchase program, Avenvi operates under the safe harbor provisions of SEC Rule 10b-18. This requires unwavering adherence to specific volume, price, and timing constraints designed to maintain market integrity and prevent manipulative trading practices. Additionally, Avenvi manages our physical properties to ensure compliance with local zoning ordinances and the specialized environmental codes required for high-capacity compounding laboratories.

Consumer Product Regulation

MagneChef~~-branded~~, ~~products~~our ~~are~~80%-owned consumer brand, operates under the regulatory purview of agencies governing household goods and intellectual property. Our products are subject to ~~regulation~~the safety standards enforced by the Consumer Product Safety Commission (CPSC), asand ~~well~~the asadvertising ~~applicable~~substantiation requirements ~~product~~of ~~labeling,~~the Federal Trade Commission (FTC). Given that MagneChef’s value is derived from its proprietary magnetic heat-conduction ~~safety~~technology, we prioritize the maintenance and ~~advertising~~protection ~~requirements.~~of ~~The~~our ~~Company~~patent ~~monitors~~portfolio ~~relevant~~through ~~regulatory~~regular ~~updates~~filings towith ~~ensure~~the ~~MagneChef-branded~~U.S. ~~products~~Patent ~~continue~~and Trademark toOffice ~~meet~~(USPTO). ~~applicable~~This ~~safety~~ensures ~~standards,~~that ~~including~~our ~~those~~unique ~~concerning~~innovations ~~heat~~remain ~~resistance~~legally ~~and~~protected ~~material~~as ~~safety~~we scale our direct-to-consumer presence.

The Company maintains internal compliance protocols and engages legal and regulatory consultants as needed to ensure adherence to applicable laws and industry standards across all subsidiaries and operating areas.

Marketing

The Company’s employs a multi-channel marketing ~~strategy~~and issales strategy designed to ~~support~~leverage the ~~growth~~vertical integration of ~~its~~our ~~pharmaceutical,~~healthcare ~~telehealth~~and consumer portfolios. Our approach focuses on high-conversion digital acquisition, ~~real~~strategic ~~estate~~demographic targeting, and ~~consumer~~the ~~product~~utilization of proprietary ~~operations~~technology to drive patient retention and brand loyalty across our diverse subsidiaries. ~~Marketing~~By ~~activities~~maintaining ~~are~~control ~~conducted~~over ~~through~~both athe ~~combination~~clinical consultation ofand ~~digital~~the ~~advertising,~~pharmaceutical ~~strategic~~fulfillment ~~partnerships~~process, ~~professional~~we ~~referrals~~are able to execute marketing campaigns that offer a seamless, high-value ~~and~~consumer ~~internal~~experience ~~cross~~while maintaining a lower cost of customer acquisition (CAC) compared to non-~~brand~~integrated ~~promotion~~competitors.

~~Pharmacy~~Health and ~~Telehealth Services~~Wellness

~~Marketing~~Our marketing efforts for RxCompound, Mister Meds, and Peaks, ~~and~~are ~~DOConsultations~~centered ~~target~~on ~~licensed~~digital-first ~~healthcare~~strategies ~~providers~~that prioritize search engine optimization (SEO), ~~prospective~~targeted ~~patients~~social media engagement, and ~~affiliated~~performance-based ~~businesses~~digital advertising. We focus on educating consumers about the clinical ~~These~~benefits ~~efforts~~of ~~include~~customized ~~direct~~compounding and the convenience of our asynchronous telemedicine platforms. For Mister Meds, our strategy specifically targets high-~~to-consumer~~demand ~~(DTC)~~therapeutic ~~outreach~~areas, ~~through~~utilizing ~~digital~~data-driven ~~channels~~insights ~~such~~to asreach ~~search~~patients ~~engine~~in ~~optimization~~licensed ~~(SEO)~~jurisdictions, ~~email~~such ~~marketing~~as Texas, where ~~and~~we ~~social~~have ~~media~~established ~~advertising~~a strong dispensing presence. ~~Additionally,~~Peaks ~~the~~and ~~Company~~DOC ~~develops~~serve ~~partnerships~~as ~~with~~a ~~fitness~~primary ~~centers,~~funnel ~~wellness~~for ~~clinics~~these operations, ~~and~~utilizing ~~medical~~a ~~offices~~streamlined user interface to ~~promote~~convert ~~its~~digital ~~compounded~~traffic ~~medications~~into ~~and~~long-term ~~asynchronous~~patients ~~telehealth~~through ~~consultations~~a frictionless onboarding and consultation process.

~~Real~~Our strategy for Villas emphasizes community-based outreach, culturally relevant digital content, and targeted traditional media to build ~~Estate~~trust ~~Services~~within its niche market. By focusing on specialized wellness and sexual health—areas often underserved by traditional healthcare providers—Villas attracts a dedicated patient base that values personalized, in-person clinical support. This subsidiary also benefits from cross-promotional opportunities within the broader ETST ecosystem, directing patients to our digital pharmacy services for ongoing prescription fulfillment.

~~Avenvi’s~~Real ~~marketing~~Estate ~~initiatives are centered around its turnkey development services~~ and ~~financing~~Asset ~~capabilities.~~Management ~~Marketing is conducted through industry relationships and project-specific campaigns designed to attract buyers for its properties.~~Division

Avenvi has no marketing activities as it serves as foundation for managing the Company’s assets.

Consumer Products

~~MagneChef~~The ~~products~~marketing ~~are~~strategy ~~marketed~~for ~~directly~~MagneChef leverages the brand’s proprietary intellectual property to ~~consumers~~differentiate ~~through~~its ~~online~~products ~~marketplaces,~~in ~~brand-specific~~the ecompetitive direct-~~commerce~~to-consumer ~~channels,~~(DTC) ~~and~~kitchenware ~~social~~market. ~~media~~We ~~platforms. The~~utilize ~~Company~~a ~~employs~~combination ~~influencers,~~of ~~video~~influencer ~~content~~partnerships, ~~and~~video-based ~~paid~~social media todemonstrations, and ~~promote~~e-commerce ~~product~~optimization ~~features~~to ~~and~~showcase ~~patented~~the ~~innovations.~~unique ~~Marketing~~benefits ~~efforts highlight~~of ~~the~~our ~~safety,~~magnetic ~~durability,~~heat-conduction ~~and~~technology. ~~functional~~By ~~design~~focusing ofon the ~~products~~“innovative kitchen” segment, ~~with~~MagneChef targets a ~~focus~~demographic onthat values efficiency and high-~~heat~~performance ~~cooking~~technology, ~~grilling,~~allowing ~~and~~us ~~professional~~to maintain ~~kitchen~~premium ~~use~~pricing and drive brand recognition independent of our healthcare operations.

The Company adheres to all applicable advertising regulations across its marketing channels, including those governing the promotion of health-related products and services. Marketing compliance is reviewed internally and through third-party consultants to reduce regulatory risk and ensure alignment with corporate messaging.

Strategic Brand Positioning and Retention

Central to the Company’s overall marketing success is our focus on patient and customer retention. We utilize Customer Relationship Management (CRM) systems at each of our subsidiaries to provide personalized follow-ups, medication reminders, and targeted wellness content. This holistic approach not only increases the lifetime value (LTV) of each customer but also reinforces ETST’s position as a comprehensive health and wellness provider. Furthermore, our commitment to social responsibility through the ESF enhances our brand equity, demonstrating to investors and consumers alike that the Company is dedicated to healthcare accessibility and community support.

COMPETITION

The Company operates in ~~multiple~~a highly competitive and fragmented landscape across several major sectors, including pharmaceutical compounding, telemedicine, clinical wellness, real estate asset management, and ~~faces~~direct-to-consumer ~~competition~~goods. ~~from~~We compete with a ~~variety~~diverse array of ~~companies~~market participants, ranging from large, established ~~organizations~~multinational corporations with significantly greater financial resources to specialized, niche firms and emerging technology-driven startups. Our ability to ~~smaller~~compete effectively is predicated on our unique vertical integration, which ~~specialized~~allows ~~service~~us ~~providers~~to offer a value added healthcare experience.

~~Compounding~~Health ~~Pharmacies~~and wellness

~~RxCompound~~In the pharmaceutical compounding and ~~Mister~~telemedicine ~~Meds~~sectors ~~compete~~the ~~with~~Company ~~other~~faces ~~compounding~~intense ~~pharmacies,~~competition ~~including~~from ~~regional~~both traditional brick-and-mortar pharmacies ~~national~~and ~~operators~~a ~~offering~~rapidly ~~both~~expanding ~~sterile~~cohort ~~and~~of ~~non-sterile formulations.~~digital ~~Competitive~~health ~~factors~~platforms. inThe ~~this~~Company ~~segment~~competes ~~include~~with ~~licensure~~established ~~coverage~~pharmacy chains, ~~quality~~which ~~assurance~~have ~~standards,~~increasingly ~~turnaround~~integrated ~~times,~~specialty ~~customer~~pharmacy and ~~service,~~digital ~~pricing,~~prescription ~~and~~services into their models. In the ~~ability~~telemedicine tospace, ~~produce~~we ~~customized~~compete ~~formulations.~~with ~~The~~well-capitalized ~~market~~platforms isas ~~highly~~well ~~regulated,~~as ~~and~~specialized ~~compliance~~sexual ~~with~~health ~~USP~~and ~~<795>,~~wellness platforms. ~~<797>,~~Our ~~and~~competitive ~~<800>,~~advantage ~~where~~in ~~applicable,~~this ~~standards~~sector ~~are~~lies ain ~~key~~our ~~differentiator.~~ability ~~The~~to ~~Company~~seamlessly ~~believes~~link ~~its~~the ~~growing~~clinical ~~licensure~~consultation ~~footprint,~~with our proprietary pharmacy ~~investment~~fulfillment, inensuring ~~advanced~~higher ~~compounding~~quality ~~infrastructure,~~control and ~~integration~~more ~~with~~responsive ~~affiliated~~patient ~~telehealth~~care than platforms ~~provide~~that arely ~~competitive~~on ~~advantage~~third-party pharmacy networks.

6Real Estate and Asset Management

~~Telemedicine~~Avenvi ~~Services~~has no natural competitors as it serves as the foundation for managing the Company’s assets.

~~Peaks~~Consumer ~~and~~Product DOC operate in a rapidly evolving and highly competitive telehealth market. Key competitors include national telehealth platforms, vertically integrated pharmacy services, and digital health startups offering asynchronous or synchronous care. Competitive factors include platform accessibility, provider availability, regulatory compliance, pricing, and brand reputation. The Companies differentiate themselves by offering proprietary compounded medications.Innovation

~~Real~~MagneChef ~~Estate~~operates ~~Development~~in the highly saturated direct-to-consumer (DTC) kitchenware and ~~Investment~~household goods market. We compete with established premium cookware brands, as well as high-growth DTC entrants. These competitors often have larger marketing budgets and established retail partnerships. MagneChef’s competitive strategy focuses on the commercialization of its proprietary magnetic heat-conduction technology, allowing us to market a unique value proposition centered on efficiency and technological innovation. By targeting the “innovative kitchen” segment through digital-first performance marketing, we aim to capture market share from consumers seeking high-performance alternatives to traditional cookware.

Avenvi operates in the real estate development and investment sector, which is highly competitive and influenced by market cycles, interest rates, and geographic demand. Avenvi competes with local and national developers, institutional investors, and private equity firms. Competitive advantages include Avenvi’s ability to manage both project development and investment oversight in-house.8

Consumer Products

MagneChef competes with established brands in the kitchen and grilling accessory market, including companies with significant brand recognition, marketing budgets, and retail distribution. The Company competes based on innovation, product safety, and durability. The MagneChef product line is distinguished by its patented magnetic release mechanism and high-heat protection features.

Across all business segments, the Company’s ability to compete effectively depends on its continued investment in operational scalability, regulatory compliance, customer service, and innovation. The Company expects competitive pressures to intensify as regulatory frameworks evolve, and new market entrants emerge.

EMPLOYEES

As of March 31, ~~2025~~2026, the Company has 7677 employees. None of our employees are represented by a union or covered by a collective bargaining agreement. We have not experienced any work stoppages, and we consider our relationship with our employees to be good.

ITEM 1A. RISK FACTORS

A description of the risks and uncertainties associated with our business and ownership of our Class A common stock is set forth below. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The occurrence of any of the events or developments described below could materially and adversely affect our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our Class A common stock could decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See “Cautionary Note Regarding Forward-Looking Statements.”

Summary of Principal Risk Factors

● Our results of operations, as well as our key metrics, may fluctuate on a quarterly and annual basis, which may result in our failing to meet the expectations of industry and securities analysts or our investors. ● If we are unable to expand the scope of our offerings, including the number and type of products and services that we offer, the number and quality of healthcare providers serving our customers, and the number and types of conditions capable of being treated through our platform, our business, financial condition, and results of operations may be materially and adversely affected. ● If we are unable to successfully market to new customers and retain existing customers, or if evolving privacy, healthcare, or other laws prevent or limit our marketing activities, our business, financial condition, and results of operations could be harmed. ● We operate in highly competitive markets and face competition from large, well-established healthcare providers and more traditional retailers and pharmaceutical providers with significant resources, and, as a result, we may not be able to compete effectively. ● Our brand is integral to our success. If we fail to effectively maintain, promote, and enhance our brand in a cost-effective manner, our business and competitive advantage may be harmed. ● Our pharmacy business subjects us to additional healthcare laws and regulations beyond those we face with our telehealth business and increases the complexity and extent of our compliance and regulatory obligations. ● If we fail to comply with applicable healthcare and other governmental regulations, we could face substantial penalties, in which case our business, financial condition, and results of operations could be adversely affected, and we may be required to restructure our operations. ● Evolving government regulations and enforcement activities may require increased costs or adversely affect our results of operations. ● Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or customers or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. ● We may be subject to legal proceedings and litigation, including intellectual property disputes, which are costly to defend and could materially harm our business and results of operations. ● We may require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all. ● Our Series B class Preferred stock structure has the effect of concentrating voting power with our Chief Executive Officer and Director, Giorgio R. Saumat, which limits an investor’s ability to influence the outcome of important transactions, including a change in control. ● The market price of our common stock may be volatile.

~~Risks Related~~● Our pharmacy business subjects us to ~~Peaks~~additional healthcare laws and regulations beyond those we face with our telehealth business and increases the complexity and extent of our compliance and regulatory obligations. ● If we fail to comply with applicable healthcare and other governmental regulations, ~~RxCompound~~we could face substantial penalties, ~~Mister~~in ~~Meds~~which ~~Business~~case our business, ~~DOC~~financial condition, and ~~Villas~~results of operations could be adversely affected, and we may be required to restructure our operations. ● Evolving government regulations and enforcement activities may require increased costs or adversely affect our results of operations. ● Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or customers or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. ● We may be subject to legal proceedings and litigation, including intellectual property disputes, which are costly to defend and could materially harm our business and results of operations. ● We may require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all. ● Our Series B class Preferred stock structure has the effect of concentrating voting power with our Chief Executive Officer and Chairman of the Board, Giorgio R. Saumat, which limits an investor’s ability to influence the outcome of important transactions, including a change in control. ● The market price of our common stock may be volatile.

Risks Related to Health and Wellness sector

Our limited operating history and evolving business model make it difficult to evaluate our current performance or predict our future results. Because we are a relatively young company with a developing business model, investors may have limited information on which to base an investment decision. As we continue to grow and expand into new markets and offerings, our prospects must be considered in light of the risks and uncertainties associated with a developing company in a rapidly evolving industry.

If we are unable to expand the scope of our offerings, our business and financial results may suffer. Our ability to grow depends on expanding the number and types of products and services we offer, increasing the number and quality of healthcare providers on our platform, and broadening the range of treatable conditions. If we fail to do so, our ability to attract and retain customers, generate revenue, and compete effectively may be materially and adversely affected.

Failure to attract and retain customers may materially harm our business. Our growth depends on acquiring and retaining customers through marketing efforts and platform engagement. If our marketing strategies fail to generate sufficient awareness or demand, or if changes in privacy, healthcare, or marketing regulations limit our outreach, our revenue and overall performance could be negatively impacted.

Misuse or mismanagement of social media and influencer marketing may expose us to reputational and regulatory risk. While social media and celebrity influencers can enhance brand recognition, any misuse, inappropriate associations, or failure to comply with advertising regulations could lead to reputational damage, customer loss, and potential fines or penalties.

Our brand is integral to our competitive position, and any deterioration in brand equity could harm our business. We rely heavily on brand strength to differentiate ourselves in the market. If we fail to effectively promote, protect, or maintain our brand, our reputation could suffer, negatively impacting customer acquisition, retention, and partnership opportunities.

If our offerings fail to achieve or maintain market acceptance, our financial performance could be adversely affected. Failure to meet customer expectations or differentiate our services from competitors could result in slower growth, lower revenue, and reduce investor confidence.

We operate in a nascent and rapidly evolving market that may be difficult to predict. Our core business model, particularly through Peaks, ~~DOC,~~ and Villas, operates in emerging areas of telehealth and wellness. The competitive landscape is dynamic and includes risks related to to regulatory changes, industry consolidation, and shifts in consumer behavior, all of which may affect demand forecasting and business planning.

Technological innovations and alternative solutions may reduce demand for our services. Advancements in digital health, diagnostics, or pharmaceutical therapies could render our offerings less attractive or obsolete, affecting customer retention and revenue.

We face competition from larger, better-capitalized companies. Many of our competitors include large healthcare systems, retail pharmacies, and pharmaceutical manufacturers with greater brand recognition, operational scale, and financial resources, which may limit our ability to compete effectively.

9Our reliance on MOC Teledoc, our affiliated healthcare provider network, exposes us to risks related to provider recruitment, retention, clinical liability, and complex regulatory compliance. MOC Teledoc, a subsidiary operating under Peaks, manages our proprietary telemedicine platform and network of affiliated doctors to facilitate telehealth consultations. Our continued growth and ability to seamlessly fulfill prescriptions depend heavily on recruiting, retaining, and effectively managing qualified, state-licensed healthcare professionals within this network. If we encounter difficulties in expanding the MOC Teledoc network, or if we experience high turnover among affiliated providers, our capacity to handle patient volume could be severely constrained, directly impacting revenue.

~~The~~Furthermore, ~~conduct~~facilitating ofmedical ~~affiliated~~consultations ~~healthcare~~exposes ~~providers~~us ~~may~~to ~~expose~~inherent usclinical torisks. We may face vicarious liability, ~~and~~medical malpractice claims, or reputational ~~harm.~~damage ~~Our~~arising ~~reputation~~from ~~and~~the ~~legal~~clinical ~~standing~~decisions, ~~may~~conduct, ~~be affected~~or byomissions of the ~~actions~~independent ofproviders ~~healthcare~~utilizing ~~professionals~~the ~~affiliated~~MOC ~~with~~Teledoc platform. ~~Peaks~~Additionally, ~~DOC,~~we ~~Villas,~~must ~~RxCompound~~ensure our operational relationship with MOC Teledoc strictly adheres to varying state-specific Corporate Practice of Medicine (CPOM) doctrines, orwhich ~~Mister~~prohibit ~~Meds~~non-physician entities from interfering with the independent clinical judgment of licensed medical professionals. Any ~~unethical~~regulatory scrutiny or legal challenges regarding the operational independence or classification ~~noncompliant~~of ~~conduct~~these ~~may~~physicians could result in ~~legal~~significant ~~exposure~~fines, orcostly ~~loss~~mandatory ofrestructuring, ~~trust~~or insevere disruptions to our ~~platform~~telehealth operations.

Poor customer support may damage our reputation and financial performance. A failure to provide effective support to patients and providers may lead to dissatisfaction, complaints, and erosion of customer loyalty, which could impair our competitive position and revenue.

Acquisitions and strategic investments could fail to deliver expected benefits and may introduce additional risks. We may pursue acquisitions or strategic partnerships to accelerate growth, but such transactions carry risks related to integration, unforeseen liabilities, operational disruption, and dilution to existing shareholders.

Macroeconomic conditions may negatively affect demand for our services. Economic downturns, inflation, or disruptions in the healthcare or real estate markets may reduce consumer spending or investor confidence, thereby impacting our financial performance.

Our mobile experience is critical to user engagement and retention. A significant portion of users interact with our platform via mobile devices. Any issues with mobile functionality, performance, or compatibility may impair our ability to retain and grow our customer base.

We rely on uninterrupted internet and mobile network access to operate our platform. Any outages or interruptions in internet or cellular connectivity could disrupt service availability, reduce customer satisfaction, and harm our reputation. Failures, delays, or breaches by these vendors may impair our ability to provide services, fulfill prescriptions, or maintain operational continuity.

Supply chain disruptions could affect product availability and customer satisfaction. Delays or shortages in the supply of pharmaceutical ingredients, packaging, or delivery services could affect our ability to meet demand and damage our brand.

Pharmacy operations are subject to complex healthcare regulations and heightened compliance risk. RxCompound and Mister Meds must adhere to a wide array of state and federal pharmacy regulations, including those beyond telehealth services. Noncompliance could result in fines, license suspensions, or legal action.

We rely on third-party payment processors and must comply with evolving payment regulations. Any failure in payment processing systems or regulatory compliance could interrupt transactions, harm user experience, and reduce revenue.

Inaccurate or ineffective pricing strategies could hinder our competitiveness. If our pricing does not reflect market dynamics or customer expectations, we may face reduced demand, margin compression, or lost opportunities for partnership growth.

Our business depends on the leadership team’s continuity and expertise. The loss of key executives or inability to recruit experienced leadership could impair our ability to execute on strategy and manage daily operations effectively.

Our growth relies on attracting and retaining skilled employees. An inability to hire or retain qualified personnel may constrain our innovation capacity, operational execution, and scalability.

We rely on centralized inventory locations for order fulfillment. Our inventory is currently housed at RxCompound’s facility in Miami, Florida and Mister Meds’ facility in Abilene, Texas. A disruption, natural disaster, or facility damage at either site could materially impair our ability to fulfill orders and meet customer expectations.

10Risks Related to Asset Management

Risks Related to Avenvi Business

Market volatility could affect asset values and returns. Avenvi’s real estate assets are influenced by macroeconomic factors such as inflation, interest rates, and regional market conditions. A downturn could lead to reduced valuations, delayed projects, and lower development returns.

Development projects carry execution and cost risks. Delays, cost overruns, zoning or environmental issues, and changing market demand may affect the success and profitability of Avenvi’s development projects.

Limited access to financing could constrain Avenvi’s growth. Avenvi’s ability to pursue and complete development projects depends on access to capital and credit. Rising interest rates or unfavorable lending terms may limit its ability to fund future activities.

Avenvi’s performance is closely tied to ETST’s strategic direction. As Avenvi manages investments for Earth Science Tech, Inc., changes in ETST’s strategic priorities or liquidity—such as decisions surrounding the $5 million share repurchase program—may affect Avenvi’s operations and outcomes.12

Avenvi’s performance is closely tied to the Company’s strategic direction. As Avenvi manages physical infrastructure and real estate investments for Earth Science Tech, Inc., changes in ETST’s strategic priorities, capital allocation, or liquidity may directly affect Avenvi’s development operations and financial outcomes.

Regulatory compliance burdens may increase costs or delay projects. Avenvi’s operations are subject to various zoning, disclosure, tax, and environmental regulations. Changes in these laws may increase compliance costs or restrict development opportunities.

Shifts in demand may affect project success. Changes in real estate demand—particularly due to economic trends or remote work—may reduce demand for Avenvi’s residential or commercial developments.

Reputational risks may result from underperformance or mismanagement. Failure to meet development expectations or mismanagement of capital—especially in relation to ~~ETST~~the Company’s resources—may result in reputational damage or increased scrutiny from shareholders and regulators.

Risks Related to MagneChef Consumer

We may be unable to protect our intellectual property rights, including those associated with ~~Magne~~MagneChef. The ~~Magne~~MagneChef product line depends on patented technologies and trademarked branding. Failure to enforce or maintain these rights may result in loss of exclusivity, brand dilution, or increased competition.

Product liability or safety issues related to ~~Magne~~MagneChef could result in reputational harm or legal exposure. If any Magne product is found to be be defective, unsafe, or misused, we may face product recalls, regulatory inquiries, litigation, or consumer dissatisfaction that adversely impacts sales and brand equity.

~~Magne~~MagneChef operates in a competitive consumer goods market with limited barriers to entry. Larger companies with established distribution, pricing power, or marketing budgets may limit our ability to gain or maintain market share.

Shifts in consumer behavior may impact demand for ~~Magne~~MagneChef products. Changes in household spending patterns, cooking trends, or consumer preferences could reduce demand and impact overall product performance.

Risks Related to Governmental Regulation

We are subject to extensive, complex, and evolving government regulations. Our operations—particularly those involving RxCompound, Mister Meds, Peaks, DOC, and Villas—are subject to a broad range of federal, state, and local regulations governing healthcare, pharmacy operations, telemedicine, and patient privacy. Failure to comply with these regulations could result in substantial penalties, operational restrictions, or reputational harm. Regulatory requirements may change without notice, potentially requiring significant expenditures to ensure compliance.

Noncompliance with federal or state healthcare laws could result in civil or criminal penalties. If any of our business practices are found to violate anti-kickback statutes, false claims laws, HIPAA, or other healthcare-related laws, we could face fines, exclusion from federal healthcare programs, or other enforcement actions that materially affect our operations.

Changes in healthcare policy and reimbursement structures could impact our business model. Modifications to federal or state healthcare programs, insurance coverage mandates, or telehealth reimbursement policies may affect customer access, demand for our services, or the financial viability of our offerings.

Our pharmacy operations are subject to heightened regulatory scrutiny. RxCompound and Mister Meds must comply with numerous state pharmacy board regulations, DEA requirements for controlled substances, and FDA rules for compounded medications. Any violation—whether intentional or inadvertent—could result in license suspension, fines, or criminal investigation.

Evolving telemedicine regulations create compliance uncertainty. As telehealth laws continue to evolve across jurisdictions, we must adapt to inconsistent requirements around prescribing, physician licensure, patient consent, and recordkeeping. Failure to keep pace with these changes may limit our geographic reach or lead to regulatory violations.13

Evolving telemedicine regulations create compliance uncertainty. As telehealth laws continue to evolve across jurisdictions, we must adapt to inconsistent requirements around prescribing, physician licensure, patient consent, and record keeping. Failure to keep pace with these changes may limit our geographic reach or lead to regulatory violations.

Privacy and data protection laws may impose additional burdens on our business. We are subject to HIPAA and other federal and state privacy laws governing the collection, storage, and transmission of personal health information. Breaches or noncompliance may result in fines, litigation, and loss of customer trust.

Our compounding pharmacy operations rely on regulatory exemptions that are subject to strict and evolving FDA interpretation, particularly regarding drug shortages. RxCompound and Mister Meds operate under Section 503A of the FDCA, which provides exemptions from standard FDA drug approval processes provided certain conditions are met, including restrictions on compounding drugs that are ‘essentially a copy’ of commercially available products. We rely on the FDA’s drug shortage list to legally compound certain high-demand medications. If the FDA removes key active pharmaceutical ingredients from the shortage list, alters its enforcement discretion, or determines that our customized formulations do not demonstrate sufficient clinical difference from mass-market drugs, our pharmacies could be forced to immediately halt production of highly profitable product lines, which would materially and adversely affect our revenue.

Future regulatory developments may increase compliance costs or restrict operations. Emerging policies—such as new FDA oversight of compounded drugs, increased scrutiny of health tech platforms, or restrictions on influencer marketing in healthcare—could materially affect how we conduct business.

Risks Related to Intellectual Property and Legal Proceedings

We may be unable to adequately protect our intellectual property rights. Our success depends in part on our ability to protect proprietary technologies, trademarks, trade secrets, and other intellectual property associated with our brands, including ~~Magne~~MagneChef. If we fail to adequately secure or enforce our rights, we may lose competitive advantages, experience brand dilution, or face increased competition.

Third parties may infringe on our intellectual property or challenge its validity. Unauthorized use or misappropriation of our intellectual property could harm our reputation and market position. In some cases, we may be forced to initiate costly and time-consuming legal proceedings to protect our rights or defend against infringement claims.

We may be subject to claims alleging intellectual property infringement. As we expand our offerings, there is a risk that third parties may allege that our technologies, branding, or marketing strategies infringe on their intellectual property rights. Even if such claims lack merit, they could lead to litigation, financial liabilities, or reputational damage.

Litigation or regulatory investigations could materially impact our operations. We may be involved in legal proceedings or regulatory actions in the normal course of business, including those related to employment practices, patient care, privacy violations, product liability, or contractual disputes. Any such proceedings could result in substantial costs, diversion of management attention, or adverse judgments.

We may not be adequately insured against certain legal risks. While we maintain liability and business insurance, coverage may be unavailable or insufficient for certain types of intellectual property claims, regulatory actions, or class-action lawsuits. This may result in out-of-pocket expenses that adversely affect our financial position.

Settlement obligations or adverse rulings could affect financial results. If we are required to settle a legal claim or if a court issues a judgment against us, we could face significant financial liabilities or operational restrictions, which may materially affect our business and results of operations.

1214

Risks Related to the Company, Results of Operations, and Additional Capital Requirements

The Company has a history of net losses, anticipates increasing expenses in the future, and may not be able to maintain profitability.

The Company’s results of operations, as well as our key metrics, may fluctuate on a quarterly and annual basis, which may result in failure to meet the expectations of industry and securities analysts or its investors.

Peaks relies significantly on revenue from customers purchasing subscription-based prescription products and services and may not be successful in expanding its offerings.

The requirements of being a public company have strained and may continue to strain the Company’s resources, divert management’s attention, and may result in litigation.

The Company may require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all.

If the Company’s estimates or judgments relating to its significant accounting policies prove to be incorrect, the results of operations could be adversely affected.

Adverse tax laws or regulations could be enacted, or existing laws could be applied to the Company or to customers, which could subject us to additional tax liability and related interest and penalties, increase the costs of the Company’s offerings, and adversely impact our business.

Certain U.S. state tax authorities may assert the Company has a state nexus and seek to impose state and local income taxes which could harm the results of operations.

Risks Related to Ownership of the Company Securities

~~Trading~~Our ~~in our~~ common stock is currently quoted only on the ~~Pink~~OTCID ~~Exchange~~Marketplace, ~~has~~which ~~been~~may ~~subject~~have toan ~~wide~~unfavorable ~~fluctuations~~impact on our stock price and liquidity.

Our common stock is currently quoted only on the OTC Pink Marketplace, which may have an unfavorable impact on our stock price and liquidity.

The regulation of penny stocks by SEC and FINRA may discourage the tradability of our securities.

Florida law, our Articles of Incorporation, and our by-laws provide for the indemnification of our officers and directors at our expense, and correspondingly limits their liability, which may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be expended for the benefit of officers and/or directors.

We do not intend to pay cash dividends on any investment in the shares of stock of our Company and any gain on an investment in our Company will need to come through an increase in our stock’s price, which may never happen.

Because our securities are subject to penny stock rules, you may have difficulty reselling your shares.

Our common stock market prices may be volatile, which substantially increases the risk that investors may not be able to sell their Securities at or above the price that was paid for the security.

Because we may issue additional shares of our common stock, investment in our company could be subject to substantial dilution.

FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.

The issuance of shares to enter acquisitions may have a significant dilutive effect.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 1C. CYBERSECURITY

~~ETST~~The Company recognizes the growing importance of cybersecurity. The company employs a dedicated IT infrastructure department led by Chris Rose. The IT department assumes the primary responsibility for overseeing our cybersecurity risk exposure across the entire organization. ~~This~~ This includes evaluating, assessing, and enhancing cybersecurity practices.

Initial Risk Assessment

Our ~~CTO~~technology department conducts regular IT and Security risk assessments. This involves employee sit-alongs, inventorying all tech systems and assets, and reviewing existing practices, procedures, and policies. The findings are meticulously cataloged. Action plans are developed and addressed in priority ranked order. These assessments are updated quarterly, addressing new and outstanding risks and remediation plans.

Third-Party Engagement

To expedite security policy changes, active threat monitoring, infrastructure enhancements, device management, and endpoint security, the company engages additional third-party IT consultants.

ITEM 2. PROPERTY AND EQUIPMENT

The Company’s Subsidiaries RxCompound and Mister Meds use a variety of pharmaceutical compounding equipment in its operations. ~~Most~~ Most of the equipment used by the Company is owned outright by the Company, but the Company does lease certain equipment. The leases for such equipment contain terms that are customary in the industry in which the Company operates. On March 31, ~~2025~~2026, the Company had approximately $1,~~384~~520,~~110~~000 in property and equipment net.

ITEM 3. LEGAL PROCEEDINGS

From time to time, in the ordinary course of business, we may become involved in legal proceedings seeking monetary damages or other remedies. The ultimate outcome and potential liability, if any, arising from such matters cannot be predicted. As of the date hereof, there are no pending or, to our knowledge, threatened legal actions against us, our officers, or directors in their official capacities, or involving our properties, that, in the opinion of management, are likely to have a material adverse effect on our financial condition, results of operations, or cash flows.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

Our common stock is currently quoted on the ~~OTC~~OTCID ~~Pink~~ Market under the symbol “ETST.” Our common stock has been quoted on the ~~OTC~~ ~~Pink~~ OTCID Market since ~~October~~July 61, ~~2021~~2025, under the symbol “ETST”. Because we are quoted on the ~~OTC~~OTCID ~~Pink~~ Market, our securities may be less liquid, receive less coverage by security analysts and news media, and generate lower prices than might otherwise be obtained if they were listed on a national securities exchange.

~~The following table sets forth the high and low bid quotations for our common stock as reported in the Pink for the periods indicated.~~16

The following table sets forth the high and low bid quotations for our common stock as reported in the OTCID for the periods indicated.

Fiscal Year Ending March 31^st, 2026	Low		High
First Quarter – reported June 30, 2025	$	0.108	$	0.194
Second Quarter – reported September 30, 2025	$	0.17	$	0.21
Third Quarter – reported December 31, 2025	$	0.13	$	0.237
Fourth Quarter – reported March 31, 2026	$	0.0759	$	0.16

Fiscal Year Ending March 31^st, 2025	Low		High
First Quarter – reported June 30, 2024	$	0.24	$	0.279
Second Quarter – reported September 30, 2024	$	0.14	$	0.1799
Third Quarter – reported December 31, 2024	$	0.1134	$	0.129
Fourth Quarter – reported March 31, 2025	$	0.0115	$	0.13

Fiscal Year Ending March 31st, 2024	Low		High
First Quarter – reported June 30, 2023	$	0.0497	$	0.0497
Second Quarter – reported September 30, 2023	$	0.051	$	0.066
Third Quarter – reported December 31, 2023	$	0.051	$	0.0699
Fourth Quarter – reported March 31, 2024	$	0.066	$	0.067

HOLDERS

As of March 31, ~~2025~~2026, there were ~~209~~205 ~~beneficial~~ holders of record of the Company’s common stock. A greater number of holders are “street name” or beneficial holders, whose shares or records are held by banks, brokers and other financial institutions.

DIVIDENDS

We have not paid any dividends on our common stock since our inception.

The declaration of any future cash dividends is at the discretion of our board of directors and depends upon our earnings, if any, our capital requirements and financial position, our general economic conditions, and other pertinent conditions.

UNREGISTERED SALES OF SECURITIES

The Company did not sell any equity securities during the fiscal year ended March 31, ~~2025~~2026. The Company has not sold any equity securities since early 2023.

EQUITY COMPENSATION PLAN INFORMATION

The Company currently does not have an equity compensation plan in place.

COMMON STOCK

The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of our stockholders. The holders of the common stock have the sole right to vote, except as otherwise provided by law, by our articles of incorporation, or in a statement by our board of directors in a Preferred Stock Designation.

In addition, such holders are entitled to receive ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds, subject to the payment of preferential dividends or other restrictions on dividends contained in any Preferred Stock Designation, including, without limitation, the Preferred Stock Designation establishing a series of preferred stock described above. In the event of the dissolution, liquidation or winding up of Earth Science Tech, Inc., the holders of our common stock are entitled to share ratably in all assets remaining after payment of all our liabilities, subject to the preferential distribution rights granted to the holders of any series of our preferred stock in any Preferred Stock Designation, including, without limitation, the Preferred Stock Designation establishing a series of our preferred stock described above.

1517

The holders of the common stock do not have cumulative voting rights or preemptive rights to acquire or subscribe for additional, unissued or treasury shares in accordance with the laws of the State of Florida. Accordingly, excluding any voting rights granted to any series of our preferred stock, the holders of more than 50 percent of the issued and outstanding shares of the common stock voting for the election of directors can elect all of the directors if they choose to do so, and in such event, the holders of the remaining shares of the common stock voting for the election of the directors will be unable to elect any person or persons to the board of directors. All outstanding shares of the common stock are fully paid and non-assessable.

The laws of the State of Florida provide that the affirmative vote of a majority of the holders of the outstanding shares of our common stock and any series of our preferred stock entitled to vote thereon is required to authorize any amendment to our articles of incorporation, any merger or consolidation of Earth Science Tech, Inc. with any corporation, or any liquidation or disposition of any substantial assets of Earth Science Tech, Inc.

PREFERRED STOCK

On April 21, 2022, the Company’s Board of Directors adopted articles of incorporation in the state of Nevada authorizing, without further vote or action by the stockholders, the creation, out of the unissued shares of the Company’s preferred stock, $0.001 par value Series B Preferred Stock. The Board of Directors is authorized to establish, from the authorized and unissued shares of Preferred Stock, one or more classes or series of shares, to designate each such class and series, and fix the rights and preferences of each such class of Preferred Stock; which class or series shall have such voting powers, such preferences, relative, participating, optional or other special rights, and such qualifications, limitations or restrictions as shall be stated and expressed in the resolution or resolutions providing for the issuance of such class or series of Preferred Stock as may be adopted from time to time by the Board of Directors prior to the issuance of any shares thereof. The articles of incorporation and designation authorize the issuance of 1,000,000 shares of Preferred Stock, of which 1,000,000 shares have been designated as Series B Preferred Stock, of which 1,000,000 shares of Series B are issued and outstanding as of March 31, 2025. Each issued and outstanding share of Series B Preferred Stock shall be entitled to the number of votes equal to the result of: (i) 1.5 multiplied by the addition sum of: (A) the number of shares of Common Stock issued and outstanding at the time of such vote; and (B) the number of votes in the aggregate of any outstanding shares of any class of preferred stock of the Corporation (other than the Series B Preferred Stock), if any, at the time of such vote; with such sum divided by (ii) the total number of shares of Series B Preferred Stock issued and outstanding at the time of such vote, at each meeting of shareholders of the Corporation with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration, including the election of directors. Holders of Series B Preferred Stock shall vote together with the holders of Common Shares (and any other outstanding class of preferred stock of the Corporation (other than the Series B Preferred Stock), if any.

WARRANTS

The Company does not currently have any warrants issued or outstanding.

ISSUER REPURCHASES OF EQUITY SECURITIES

During the twelve months ended March 31, ~~2025~~2026, the Company repurchased 142,~~583~~728,~~916~~000 shares of its common stock for $1471,~~465~~410,~~837.70,~~ in private transactions through Stock Purchase Agreements with certain shareholders. On June 26, 2024, the Company repurchased 914,108 shares from an investor at $0.1734 per share in cash. On July 10, 2024, the Company repurchased a total of 17,000 shares from two investors at $0.28 per share in cash. On July 30, 2024, the Company repurchased 1,500,000 shares from an investor at $0.13 per share in cash. On August 6, 2024, the Company repurchased 2,500,000 shares from an investor at $0.105 per share in cash. On August 26, 2024, the Company repurchased 70,000 shares from an investor at $0.105 per share in cash. On September 18, 2024, the Company repurchased 549,061 shares from an investor at $0.21 per share in cash. On October 3, 2024, the Company repurchased 500,000 shares from an investor at $0.11 per share in cash. On October 28, 2024, the Company repurchased 115,385 shares from an investor at $0.105 per share in cash. On November 15, 2024, the Company repurchased 355,967 shares from an investor at $0.1685 per share in cash. On January 10, 2025, the Company repurchased 2,500,000 shares from an investor at $0.06 per share in cash. These shares were cancelled. On January 13, 2025, the Company repurchased 1,500,000 shares from an investor at $0.06 per share in cash. On January 15, 2025, the Company repurchased 666,667 shares from an investor at $0.06 per share in cash. On January 15, 2025, the Company repurchased 333,334 shares from an investor at $0.06 per share in cash. These shares were cancelled. On January 15, 2025, the Company repurchased 266,667 shares from an investor at $0.06 per share in cash. On March 17, 2025, the Company repurchased 2,000,000 shares from an investor at $0.05 per share in cash. These shares were cancelled.

ISSUER CANCELLATION OF EQUITY SECURITIES

During the twelve months ended March 31, ~~2025~~2026, the Company cancelled 504,~~000~~023,296 shares of its common ~~stock through a Board Consent because the shares were not intended for use or benefit by the Company~~.

On January 27, 2026, the Company finalized the cancellation of 250,000 shares of common stock previously issued to a private shareholder. This action was authorized by the Board of Directors on May 13, 2025, following a review by the Company’s former Receiver, who determined that there was no record of consideration for the original issuance and that the holder had previously agreed to surrender the shares. The cancellation was recorded effective January 27, 2026, the date of final processing by the transfer agent. All of these shares have been returned to the status of authorized but unissued share.

OPTIONS

The Company has not granted any options since its inception.

TRANSFER AGENT

The Company’s transfer agent is Continental Stock Transfer & Trust, Co., 1 State Street, 30th Floor, New York, NY 10004.

ITEM 6. SELECTED FINANCIAL DATA

Not applicable to a “smaller reporting company” as defined in Item 10(f)(1) of SEC Regulation S-K.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations for the years ended March 31, ~~2025~~2026, and March 31, ~~2024~~2025, should be read in conjunction with our consolidated financial statements and the notes to those statements that are included elsewhere in this Annual Report on Form 10-K. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations, and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements due to several factors. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.

OVERVIEW

~~The~~ETST ~~Company’s~~operates ~~current~~as ~~operations~~a ~~include~~diversified ~~compounding~~holding ~~pharmaceuticals,~~company ~~telemedicine~~focused on the health and ~~real~~wellness ~~estate~~sector. ~~development~~The ~~through~~Company’s ~~its~~principal ~~wholly~~operating ~~owned~~strategy ~~subsidiaries:~~is ~~RxCompoundStore.com,~~to ~~LLC~~build ~~(“RxCompound”),~~a ~~Peaks~~vertically ~~Curative,~~integrated ~~LLC~~healthcare ~~(“Peaks”),~~platform ~~Avenvi,~~that ~~LLC~~combines ~~(“Avenvi”), Mister~~compounding ~~Meds~~pharmacy operations, ~~LLC~~telemedicine ~~(“Mister~~platforms, ~~Meds”)~~clinical support, and ~~Earth~~direct-to-patient ~~Science Foundation, Inc~~fulfillment. ~~(“ESF”).~~The ~~Subsequent to the reporting period, the~~ Company’s ~~acquired~~healthcare ~~100%~~operations ofare ~~Las~~supported ~~Villas~~by ~~Health~~investments ~~Care,~~in ~~Inc.~~real ~~(“Villas”),~~estate ~~DOConsultations,~~and asset ~~LLC~~management ~~(“DOC”),~~activities and ana ~~80% interest~~consumer inproducts ~~MagneChef (“Magne”)~~business.

~~RxCompound,~~The ~~based~~core inof ~~Miami,~~the ~~Florida,~~Company’s isvalue aproposition ~~fully~~is ~~licensed compounding pharmacy authorized to fulfill prescriptions in~~ the ~~following~~seamless ~~states~~integration ~~and~~of ~~territories: Arizona,~~patient ~~Colorado~~care, ~~Delaware,~~from ~~Florida,~~consultation ~~Georgia,~~to ~~Illinois,~~fulfillment. ~~Indiana,~~This ~~Iowa, Maine, Maryland, Minnesota, Missouri, Nevada, New Jersey, New~~is ~~York,~~achieved ~~North~~through ~~Carolina,~~the ~~Ohio,~~synergy ~~Oklahoma,~~of ~~Pennsylvania,~~specialized ~~Rhode Island, Utah, Wisconsin and Puerto Rico~~subsidiaries. ~~RxCompound~~The isCompany’s ~~actively~~primary ~~pursuing~~operating ~~licensure in~~businesses ~~the remaining U.S. states.~~include:

~~Peaks~~Health ~~is a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound~~ and Mister Meds. The platform operates in states where either pharmacy is licensed. Through the development of its own healthcare provider network, MyOnlineConsultation.com, and ongoing licensure expansion for both pharmacies, Peaks aims to offer services nationwide.wellness

17● RxCompoundStore.com: Multi-state (Florida based) sterile/non-sterile compounding for specialized therapies; providers and patients needing access beyond retail chains. ● Mister Meds: Multi-state (Texas based) sterile/hazardous compounding center; Texas patients and referring clinicians; fast TX dispensing and hub for nearby states. ● Peaks Curative: Frictionless asynchronous consults funneling to licensed pharmacies; digitally engaged patients seeking convenience. ● DOConsultations: Virtual care brand for home-based therapies; patients wanting guided telehealth with ongoing follow-up. ● Villas Health Care: Brick-and-mortar healthcare facility designed to expand patient access.

~~Mister~~Asset ~~Meds,~~Management ~~acquired on October 1, 2024, is in Abilene, Texas. The pharmacy received full compounding licensure in March 2025. It operates out of a 5,000 sq. ft. facility owned by Avenvi~~ and includes advanced sterile compounding capabilities with both positive and negative pressure environments, as well as hazardous drug handling. Mister Meds is currently applying for licensure in states not yet serviced by RxCompound.Other

	●	Avenvi: A diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company’s ongoing $10 million share repurchase program.

	●	MagneChef: A direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property.

Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Our expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. We combine compassionate, personalized care with clear, trustworthy education — empowering you to take control of your health with confidence.

RESULTS OF OPERATIONS

The following tables set forth summarized cost of revenue information for the year ended March 31, ~~2025~~2026, and for the year ended March 31, ~~2024~~2025, respectively.

For the Year Ending March 31,

2025

2024

$ Change

% Change

2026

2025

$ Change

% Change

Revenue

3335,~~117~~695,~~624~~614

1133,~~953~~117,~~635~~624

212,~~163~~577,~~989~~990

~~177~~8

Cost of goods sold

810,~~817~~207,~~488~~557

48,~~124~~817,~~139~~488

41,~~692~~390,~~349~~069

~~114~~16

Gross Profit

2425,~~300~~488,~~136~~057

724,~~828~~300,~~496~~136

161,~~471~~187,~~640~~921

~~210~~5

We ~~had~~generated ~~product~~ sales of $3335,~~117~~695,~~624~~614 and a gross profit of $2425,~~300~~488,~~136~~057, representing a gross margin of 7371% for the year ended March 31, ~~2025~~2026, compared ~~with~~to product sales of $1133,~~953~~117,~~635~~624 and a gross profit of $724,~~828~~300,~~496~~ 136, representing a gross margin of 6573% infor ~~year end March 31, 2024. The revenue increase in~~ the year ended on March 31, 2025~~, compared with the year ended on March 31, 2024, is primarily due to an increase in the demand for compounded medications~~.

The ~~Gross~~increase ~~Margin~~in ~~increase~~product issales for the year ended March 31, 2026, was primarily driven by higher demand for compounded medications across the Company’s ~~subsidiaries’~~platforms, including increased ~~buying~~prescription ~~power,~~volumes ~~which~~generated ~~provides~~through the ~~ability~~Company’s totelemedicine ~~negotiate~~channels and ~~better~~customer ~~prices~~portals. onGrowth ~~raw~~was ~~active~~supported ~~ingredient~~by ~~products~~continued expansion of the Company’s integrated platform, which connects patient intake, prescribing, and fulfillment.

1820

~~For~~Gross ~~the~~profit ~~year~~increased ~~ended~~in ~~March~~absolute ~~31,~~dollars; ~~2025~~however, ~~the~~gross ~~Company~~margin ~~had~~decreased afrom ~~net~~73% ~~income~~to of71%. ~~approximately~~The ~~$3,272,000~~decline ~~compared~~in togross amargin ~~net~~was ~~income~~primarily ~~from~~attributable to ~~continuing~~lower ~~operations of~~average ~~approximately~~selling ~~$812,000~~prices ~~for~~resulting ~~the~~from ~~year~~competitive ~~ended~~market ~~March~~conditions ~~31,~~and ~~2024~~changes in product mix.

Additionally, cost of goods sold increased proportionally at a higher rate than revenue, driven by factors such as ingredient cost variability, fulfillment-related costs, and pricing strategies implemented to support volume growth. Management continues to monitor pricing, supplier costs, and product mix in order to optimize margins while maintaining competitive positioning and supporting demand.

OPERATING EXPENSES

	For years ended March 31,
	2025			2024			$ Change			% Change
	2026			2025			$ Change			% Change
Salaries Expense		14,115,643			4,358,917			9,756,726			224	%
Salaries, wages and benefits		13,776,033			14,115,643			(339,610	)		-2	%
Office/General and Administrative Expenses		43,~~154~~571,~~838~~448			~~166~~4,~~976~~154,838			3(583,~~987,862~~390	)		~~2388~~-14	%
Bank Charges		1,~~066~~006,~~577~~026			~~422~~1,~~970~~066,577			~~643~~(60,~~607~~551	)		~~152~~-6	%
Advertising & marketing		~~836~~2,~~860~~840,553			25836,~~283~~860			~~811~~2,~~577~~003,693			~~3214~~239	%
Legal & Professional Fees		~~305~~221,~~932~~179			1305,~~774,182~~932			(184,~~468,250~~753	)		83-28	%
Insurance		~~180~~168,~~281~~353			5180,~~363~~281			~~174~~(11,~~918~~928	)		~~3262~~-7	%
Depreciation and Amortization		151,655			149,749			1,906			1	%
Operating lease cost		180,753			98,434			82,318			83	%
Utilities		40,392			15,368			25,024			163	%
Depreciation and Amortization		284,396			53,951			230,445			427	%
Rent expense		-			10,797			(10,797	)		(100	)%
Utilities		130,790			39,661			91,129			229	%
Miscellaneous		-			6,542			(6,542	)		(100	)%
Total operating expenses		22,179,531		$	20,852,178		$	1,327,353			6	%
Total operating expenses		20,852,178		$	6,936,147		$	13,916,031			67	%
Other income/expenses
Dividend Income		915,~~123~~458			-9,141			96,~~123~~317			~~100~~69	%
Interest earned		17			-			17			100	%
Net realized gain on sale of investments		671,528			300,162			371,366			124	%
Net realized gain on sale of investments		300,162			-			300,162			100	%
Unrealized Gain/Loss of fair value changes of investments		(957,118	)		(365,661	)		(591,457	)		162	%
Unrealized Gain/Loss of fair value changes of investments		(365,661	)		-			(365,661	)		(100	)%
Other		67,194			-			67,194			100	%
Interest Expenses		(2116,~~189~~327	)		(6721,~~207~~189	)		~~(46~~4,~~018~~862	)		~~(68~~-23	)%
Net Income before taxes		3,~~370~~089,~~410~~261			~~825~~3,~~142~~370,410			2(281,~~545,268~~149	)		~~308~~-8	%
Income Taxes		~~116~~(511,~~776~~676	)		13116,~~003~~776			~~103~~(628,~~773~~452	)		~~798~~-538	%
Net Income(Loss)	$	3,253,635		$	812,139		$	2,559,040			312	%
Net Income		3,600,937			3,253,635			347,302			11	%
Net loss attributed to non controlling interest		-29,839			-			-29,839			-100	%
Net Income available to common stockholders’	$	3,630,776		$	3,253,635			377,141			12	%

1921

Salaries expense ~~increased~~decreased from $414,~~358~~115,~~917~~643 for the year ended March 31, ~~2024~~2025, to $1413,~~115~~776,~~643~~033 for the year ended March 31, ~~2025~~2026. ~~The company has experienced significant growth and therefore the need to increase employee count to support operations and administration.~~

~~Selling,~~The ~~general~~decrease occurred despite the Company’s operational growth and ~~administrative~~expansion ~~expenses~~of ~~increased~~its ~~from~~workforce ~~$166,976~~and was primarily attributable to $4voluntary modifications to compensation arrangements by the Company’s Chief Executive Officer,~~154~~ CEO,~~976~~ and Chief Operating Officer, ~~this~~COO, ~~increase~~who elected ~~was~~to ~~necessary~~rescind portions of their previously agreed compensation and ~~anticipated~~implemented asinterim ~~the~~compensation ~~company~~adjustments, approved by the ~~experienced~~Board ~~exponential~~of Directors. These reductions more than offset increases in personnel costs associated with headcount growth during the period.

~~Marketing~~Selling, general and administrative expenses ~~totaled~~decreased from $~~836~~4,~~860~~154,838 for the ~~twelve~~year ~~months~~ ended March 31, 2025, anto ~~increase of~~ $~~811~~3,~~577 from $25~~571,~~283~~448 for the ~~twelve~~year ~~months~~ ended ~~March~~ March 31, ~~2024~~2026. ~~This~~The ~~increase~~decrease iswas primarily ~~related~~attributable to process improvements and efficiency initiatives implemented across the Company’s operations, ~~promoting~~as ~~online~~management ~~sales~~continued ~~through~~to ~~social~~optimize ~~media~~administrative ~~marketing~~functions and ~~search~~cost ~~engines~~structures. These improvements resulted in lower operating overhead, despite the Company’s continued growth during the period.

~~Bank~~Insurance ~~charges~~expense ~~were~~totaled $1168,~~066~~353 for the fiscal year ended March 31,~~577~~ 2026, ~~this~~compared isto ~~related~~$180,281 tofor ~~merchant~~the ~~fees~~fiscal year ended March 31, ~~associated~~2025. ~~with~~The decrease was primarily attributable to the ~~increase~~Company inobtaining ~~sales~~comparable insurance coverage at lower premium rates during the current fiscal year.

~~Legal~~Lease ~~and~~cost ~~professional fees~~ totaled $~~305~~180,~~932~~753 for the ~~twelve~~fiscal ~~months~~year ended March 31, ~~2025~~2026, acompared ~~decrease~~to of $198,~~468,250~~434 ~~from $1,774,182~~ for the ~~prior period~~fiscal year ended March 31, ~~2024~~2025. The ~~decrease~~increase was inprimarily ~~legal~~attributable ~~and professional fees is due~~ to ~~reclassification~~a ofnew ~~territory~~lease ~~managers~~entered ~~fees~~into toduring the ~~category~~ offiscal ~~selling,~~year ~~general~~ended ~~and~~March ~~administrative~~31, 2026.

Marketing expenses totaled $2,840,553 for the year ended March 31, 2026, an increase of $2,003,693 from $836,860 for the year ended March 31, 2025. The increase was primarily attributable to expanded digital marketing initiatives, including higher spending on social media platforms and search engine advertising, aimed at driving online sales growth, increasing customer acquisition, and supporting higher prescription volumes across the Company’s telemedicine and e-commerce channels.

Bank charges were $1,006,026 during the twelve months ended March 31, 2026, and $1,066,577 during the twelve months ended March 31, 2025.

Legal and professional fees totaled $221,179 for the year ended March 31, 2026, a decrease of $84,753 from $305,932 for the year ended March 31, 2025. The decrease was primarily attributable to lower legal and consulting costs incurred during the period, including reduced reliance on external professional services compared to the prior year.

Management is not aware of any pending or threatened legal proceedings that would have a material adverse effect on the Company’s financial position, results of operations, or cash flows.

For the year ended March 31, 2026, the Company had a net income of approximately $3,600,000 compared to a net income of approximately $3,250,000 for the year ended March 31, 2025.

We are a smaller reporting company, as defined by 17 CFR § 229.10(f)(1). We do not consider the impact of inflation and changing prices as having a material effect on our net sales and revenues and on income from our operations for the previous two years or on continuing operations going forward.

INTEREST EXPENSE

Interest ~~expenses~~expense ~~decreased~~was to $2116,~~189~~327 induring the ~~Fiscal~~fiscal ~~Year~~year ~~Ending~~ending March 31, ~~2025~~2026, compared with $6721,~~207~~189 induring ~~Fiscal~~fiscal ~~Year~~year ~~Ending~~ending March 31, ~~2024~~2025.

INCOME TAX

Estimated taxes were calculated using the ~~2025~~2026 federal tax rate of 21%. We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

NON-GAAP FINANCIAL MEASURES

We use Adjusted EBITDA internally to evaluate our performance and make financial and operational decisions that are presented in a manner that adjusts from their equivalent GAAP measures or that supplements the information provided by our GAAP measures. Adjusted EBITDA is defined by us as EBITDA (net income (loss) plus depreciation expense, amortization expense, interest and income tax expense, minus income tax benefit), further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We use Adjusted EBITDA because we believe it clearly highlights trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures, since Adjusted EBITDA eliminates from our results specific financial items that have less bearing on our core operating performance.

We use Adjusted EBITDA in communicating certain aspects of our results and performance, including in this Annual Report, and believe that Adjusted EBITDA, when viewed in conjunction with our GAAP results and the accompanying reconciliation, can provide investors with greater transparency and a greater understanding of factors affecting our financial condition and results of operations than GAAP measures alone. In addition, we believe the presentation of Adjusted EBITDA is useful to investors in making period-to-period comparison of results because the adjustments to GAAP are not reflective of our core business performance.

Adjusted EBITDA is not presented in accordance with, or as an alternative to, GAAP financial measures and may be different from non-GAAP measures used by other companies. We encourage investors to review the GAAP financial measures included in this Annual Report, including our consolidated financial statements, to aid in their analysis and understanding of our performance and in making comparisons.

BALANCE SHEETS & CASH FLOWS STATEMENTS

	As of March 31,
	2025			2024
	2026			2025
ASSETS:
Current Assets
Cash	$	1796,~~473,228~~797		$	~~697~~1,~~721~~473,228
Accounts Receivable		129,064			235,423
Accounts Receivable, net		356,054			129,064
Equity Investments at fair value		645,438			9,352
Equity securities at fair value		1,360,040			645,438
Inventory		~~503~~682,~~938~~059			~~315~~503,~~738~~938
Deposits		338,108			9,352
Long lived assets, available for sale		371,684			-
Prepaid Expenses		20,730			—
Prepaid Expenses and other current assets		154,480			358,837
Total Current Assets		3,~~110~~721,~~505~~114			13,~~258~~110,~~234~~505
Non-Current Assets
Property and Equipment, net		1,~~384~~517,~~110~~888			~~135~~1,~~352~~384,110
Right of use asset, net		~~172~~95,~~429~~317			~~156~~172,~~517~~429
Intangible assets, net		96208,~~885~~170			2896,~~441~~885
Goodwill		2,302,792			2,302,792
Deferred tax asset, net		772,294			-
TOTAL ASSETS	$	7,066,721		$	3,881,336
Goodwill		2,654,554			2,302,792
TOTAL ASSETS	$	8,969,337		$	7,066,721
LIABILITIES AND EQUITY:
Liabilities
Accounts Payable	$	~~492~~681,~~352~~925		$	~~530~~492,~~724~~352
Accrued Expenses and other payables		2,322,022			854,719
Accrued Expenses and other current liabilities		1,150,442			2,322,022
Current portion of loans & obligations		30,592			30,592
Operating lease obligations		96,206			121,851
Short-term business loans		179,488			—
Current portion of long-term debt- other		-			30,592
Current portion of operating lease obligations		121,851			70,487
Short-term business loans		-			179,488
Total Current Liabilities		31,~~146~~928,~~305~~573			13,~~486~~146,~~522~~305
Long-Term Liabilities
Lease Liability		~~37,878~~-			8437,~~950~~878
Loans and Obligations		~~31,427~~-			6031,~~559~~427
Total Long-Term Liabilities		~~69,305~~-			~~145~~69,~~509~~305
Total Liabilities		31,~~215~~928,~~610~~573			13,~~632~~215,~~031~~610
Stockholders’ Equity
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of March 31, 2025, and March 31, 2024, respectively		1,000			1,000
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of March 31, 2026, and March 31, 2025, respectively		1,000			1,000
Common stock, par value $0.001 per share, 350,000,000 shares authorized; 295,347,903 and 309,981,819 shares issued and outstanding as of March 31, 2025, and March 31, 2024, respectively		295,348			309,982
Common stock, par value $0.001 per share, 300,000,000 shares authorized; 291,324,607 shares issued and outstanding as of March 31, 2026, and 295,347,903 issued and 294,302,607 outstanding as of March 31, 2025		291,324			295,348
Additional Paid in Capital		3130,~~480~~826,~~143~~352			31,~~593~~480,~~399~~143
Accumulated Deficit		(2724,~~738~~108,~~975~~199	)		(2927,~~655~~738,~~076~~975	)
Treasury Stock		(186,404	)		—
Treasury Stock, at cost (0 and 1,045,296 shares at March 31, 2026, and March 31, 2025, respectively)		-			(186,405	)
Total Equity		3,851,111			2,249,305
Total Stockholders’ Equity		7,010,477			3,851,111
TOTAL LIABILITIES AND EQUITY	$	7,066,721		$	3,881,336
Non-Controlling Interest		30,287			-
Total Equity		7,040,764			3,851,111
TOTAL LIABILITIES AND EQUITY	$	8,969,337		$	7,066,721

~~A summary of our changes in cash flows & Statement of Financial Position for the years ended March 31, 2025, and 2024, is provided below:~~23

~~The~~A ~~Company~~summary ~~had~~of ~~$1,473,228~~our changes in ~~Cash~~cash asflows of& ~~March~~Statement ~~31,~~of ~~2025,~~Financial ~~compared~~Position tofor ~~$697,721~~the asyears ofending March 31, ~~2024.~~2026, and 2025, is provided below:

21The Company had $796,797 in Cash as of March 31, 2026, compared to $1,473,228 as of March 31, 2025.

The Company had $~~503~~682,~~938~~059 inventory and $~~129~~356,~~064~~054 in accounts receivable as of March 31, ~~2025~~2026, compared to $~~315~~503,~~738~~938 and $~~235~~129,~~423~~064 as of March 31, ~~2024~~2025.

Equity investments are reported at fair value, totaling $1,360,040 as of March 31, 2026, and $645,438 as of March 31, 2025.

The Company ~~made~~completed ~~two~~construction ~~deposits~~of ona ~~future~~residential ~~acquisitions~~property ofduring ~~Magnefuse,~~the ~~LLC~~period, ~~Las~~which ~~Villas~~is ~~Health~~currently ~~Care,~~available ~~LLC~~for ~~and Doconsultation~~sale, ~~LLC,~~at ina ~~the~~total ~~amount~~capitalized cost of $~~280~~371,~~000, and additionally the Company has prepaid its insurance for the year~~684.

As of March 31, ~~2025~~2026, the Company made an additional ~~purchase~~purchases of equipment of approximately $1760,~~200,~~000, to expand its operations.

The Company had $~~492~~681,~~352~~925 in Accounts Payable as of March 31, ~~2025~~2026, compared to $~~530~~492,~~724~~352 as of March 31, ~~2024~~2025.

~~Accrued~~The ~~expenses~~Company ~~and~~had ~~other payables include~~ approximately $1,~~800~~150,000 in ~~officer~~accrued ~~compensation,~~expenses ~~$150,000~~and ~~payroll,~~other ~~$97,000~~current ~~merchant~~liabilities ~~accrual,~~as ~~$68,000 in~~of ~~credit~~March ~~card~~31, ~~debt~~2026, ~~payable~~compared ~~and~~to approximately $882,320,000 ~~income~~as ~~tax~~of ~~payable.~~March ~~Total current liabilities increased from $1~~31,~~486,522~~ ~~to $3,146,305~~2025.

~~Long~~Total ~~term~~current liabilities decreased from $~~145~~3,~~509~~146,305 to $691,~~305~~928,573.

~~The~~Long ~~Company~~term ~~had~~liabilities adecreased ~~Stockholders~~from ~~Equity of~~ $369,~~851,111as~~305 as of March 31, 2025, ~~compared~~ to $~~2,249,305~~0 ~~of Stockholders Equity~~ as of March 31, ~~2024~~2026. ~~This improvement is primarily due to net income of $3,253,635.~~

The Company had a Stockholders’ Equity of $7,040,764 as of March 31, 2026, compared to $3,851,111 of Stockholders Equity as of March 31, 2025. This improvement is primarily due to net income available to common stockholders of approximately $3,630,000.

STATEMENT OF CASH FLOWS

	For the Years Ending March 31,
	2025			2024
	2026			2025
Net cash provided by operating activities	$	41,~~372~~940,~~390~~863		$	14,~~206~~372,~~241~~390
Net cash used in investing activities		(1,~~881~~904,~~350~~377	)		(261,~~520~~881,350	)
Net cash used in financing activities		(1712,~~715,533~~917	)		(~~517~~1,~~886~~715,533	)
Net increase (decrease) in cash and cash equivalents		~~775~~(676,~~507~~431	)		~~661~~775,~~835~~507
Cash and cash equivalents at beginning of the period		~~697~~1,~~721~~473,228			35697,~~756~~721
Cash and cash equivalents at end of the period	$	1796,~~473,228~~797		$	~~697~~1,~~721~~473,228

CASH FLOWS FROM OPERATING ACTIVITIES

The Company’s net cash provided by operating activities was $41,~~372~~940,~~390~~863 for the twelve months ~~ending~~ended March 31, ~~2025~~2026, ~~and~~compared to $14,~~206~~372,~~241~~390 for the twelve months ending March 31, ~~2024~~2025.

CASH FLOWS FROM INVESTING ACTIVITIES

During the twelve months ending March 31, ~~2025~~2026, and March 31, ~~2024~~2025, the Company used $1,~~881~~904,~~350~~377 in investing activities and $261,~~520~~881,350, respectively.

CASH FLOWS FROM FINANCING ACTIVITIES

Net Cash used in financial activities during the twelve months ended March 31, ~~2025~~2026, was $1712,~~715~~917,~~533,~~ primarily due to the repurchase of the Company’s stock.

During the Fiscal Year ending March 31, ~~2025~~2026, the Company repurchased $1471,~~465,891~~410 of its common stock, 14and 4,~~633~~023,~~916~~296 shares were ~~cancelled,~~retired ~~and~~during ~~1,045,296~~the ~~were~~fiscal ~~held~~year inending ~~treasury as of~~ March 31, ~~2025~~2026.

FUTURE FINANCING

The ~~company~~Company ~~does~~believes its current cash flow from operations will be sufficient to fund its anticipated operating and capital requirements for the next 12 months, and we do not presently anticipate needing ~~any~~to ~~future~~raise additional dilutive financing.

STOCK BASED COMPENSATION

The Company did not issue any stock-based compensation during the fiscal year ended March 31, ~~2025~~2026.

RECENT ACCOUNTING PRONOUNCEMENTS

The company has assessed the impact of recent pronouncements on the preparation of Consolidated Financial Statements, and their impact has been disclosed in note 2.

OFF- BALANCE SHEET ARRANGEMENTS

~~None~~The Company does not have any off-balance sheet arrangements, as defined in Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future material effect on the Company’s financial condition, results of operations, liquidity, capital expenditures, or capital resources.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Not applicable to a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The financial statements required by this item are set forth at the pages indicated in Part IV, Item 15(a)(1) of this Annual Report.

2325

EARTH SCIENCE TECH, INC. AND SUBSIDIARIES

Table of Contents

Report of Independent Registered Public Accounting Firm	F-1
Report of Independent Registered Public Accounting Firms	F-1
Consolidated Balance Sheets as of March 31, 2025, and March 31, 2024	F-3
Consolidated Balance Sheets as of March 31, 2026, and March 31, 2025	F-3
Consolidated Statements of Operations for the Years Ended March 31, 2025, and March 31, 2024	F-4
Consolidated Statements of Operations for the Years Ended March 31, 2026, and March 31, 2025	F-4
Consolidated Statements of Changes in Shareholders’ Equity for the Years ended March 31, 2025, and 2024	F-5
Consolidated Statements of Changes in Stockholders’ Equity for the Years ended March 31, 2026, and 2025	F-5
Consolidated Statements of Cash Flows for the Years Ended March 31, 2025, and March 31, 2024	F-6
Consolidated Statements of Cash Flows for the Years Ended March 31, 2026, and March 31, 2025	F-6
Notes for the Consolidated Financial Statements	F-7

2426

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the ~~Board~~stockholders and the board of ~~Directors~~directors ~~and~~of

~~Stockholders of~~ Earth Science Tech, Inc.

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheet of Earth Science Tech, Inc. and ~~its~~subsidiaries ~~Subsidiaries~~ (the “Company”) as of March 31, ~~2025~~ 2026, ~~and~~ the related consolidated ~~statements~~statement of operations, stockholders’ equity, and cash flows for the year ended March 31, ~~2025~~ 2026, and the related ~~consolidated~~ notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of March 31, ~~2025~~ 2026, and the results of its consolidated operations and its cash flows for the year ended March 31, ~~2025~~2026, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence ~~regarding~~ regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

We did not identify any critical audit matters that need to be communicated.

~~/s/~~Semple, ~~Stephano~~Marchal ~~Slack~~& ~~LLC~~Cooper, LLP (PCAOB ID # ~~003523~~178)

WeCertified ~~have~~Public ~~served as the Company’s auditor since 2025.~~Accountants

~~Wayne,~~We ~~Pennsylvania~~have served as the Company’s auditor since 2026.

~~June 26~~Phoenix, ~~2025~~ AZ

June 18, 2026

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Earth Science Tech, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Earth Science Tech, Inc. and its Subsidiaries (the Company) as of March 31, ~~2024~~2025, and the related consolidated statements of operations, stockholders’ equity, and cash flows for the year ended March 31, ~~2024~~2025, and the related consolidated notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of March 31, ~~2024~~2025, and the results of its operations and its cash flows for year ended March 31, ~~2024~~2025, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matters

We did not identify any critical audit matters that need to be communicated.

/s/ Stephano Slack LLC (PCAOB ID ~~5036~~# 003523)

We have served as the Company’s auditor since ~~2024~~2025.

~~Margate~~Wayne, ~~Florida~~Pennsylvania

June 2826, ~~2024~~2025

ASSURANCE DIMENSIONS, LLC

also d/b/a McNAMARA and ASSOCIATES, LLC

TAMPA BAY: 4920 W Cypress Street, Suite 102 | Tampa, FL 33607 | Office: 813.443.5048 | Fax: 813.443.5053

JACKSONVILLE: 4720 Salisbury Road, Suite 223 | Jacksonville, FL 32256 | Office: 888.410.2323 | Fax: 813.443.5053

ORLANDO: 1800 Pembrook Drive, Suite 300 | Orlando, FL 32810 | Office: 888.410.2323 | Fax: 813.443.5053

SOUTH FLORIDA: 2000 Banks Road, Suite 218 | Margate, FL 33063 | Office: 754.800.3400 | Fax: 813.443.5053

www.assurancedimensions.com

“Assurance Dimensions” is the brand name under which Assurance Dimensions, LLC including its subsidiary McNamara and Associates, LLC (referred together as “AD LLC”) and AD Advisors, LLC (“AD Advisors”), provide professional services. AD LLC and AD Advisors practice as an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable laws, regulations, and professional standards. AD LLC is a licensed independent CPA firm that provides attest services to its clients, and AD Advisors provide tax and business consulting services to their clients. AD Advisors, and its subsidiary entities are not licensed CPA firms.

F-2

EARTH SCIENCE TECH, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF MARCH 31, ~~2025~~2026, AND ~~2024~~2025

	2025			2024
	2026			2025
	As of March 31,
	2025			2024
	2026			2025
ASSETS:
Current Assets
Cash	$	1,473,228		$	697,721
Cash and cash equivalents	$	796,797		$	1,473,228
Accounts Receivable		129,064			235,423
Accounts receivable, net		356,054			129,064
Equity Investments at fair value		645,438			—
Equity securities		1,360,040			645,438
Inventory		~~503~~682,~~938~~059			~~315~~503,~~738~~938
Deposits		338,108			9,352
Long lived assets, available for sale		371,684			-
Prepaid Expenses		20,730			—
Prepaid Expenses and other current assets		154,480			358,837
Total Current Assets		3,~~110~~721,~~505~~114			13,~~258~~110,~~234~~505
Non-Current Assets
Property and Equipment		1,384,110			135,352
Property and Equipment, net		1,517,888			1,384,110
Right of use asset, net		172,429			156,517
Right of use assets, net		95,317			172,429
Intangible assets, net		96208,~~885~~170			2896,~~441~~885
Goodwill		2,302,792			2,302,792
Deferred tax asset, net		772,294			-
TOTAL ASSETS	$	7,066,721		$	3,881,336
Goodwill		2,654,554			2,302,792
LIABILITIES AND STOCKHOLDERS’ EQUITY:
TOTAL ASSETS	$	8,969,337		$	7,066,721
Liabilities
LIABILITIES AND EQUITY:
Accounts Payable	$	492,352		$	530,724
Current Liabilities
Accrued Expenses and other payables		2,322,022			854,719
Accounts payable	$	681,925		$	492,352
Current portion of loans & obligations		30,592			30,592
Accrued expenses and other payables		1,150,442			2,322,022
Short-term business loans		179,488			—
Current portion of operating lease obligations		96,206			121,851
Current portion of operating lease obligations		121,851			70,487
Current portion of loans & obligations		-			30,592
Total Current Liabilities		3,146,305			1,486,522
Short-term business loans		-			179,488
Total Current Liabilities		1,928,573			3,146,305
Long-Term Liabilities
Lease Liability		~~37,878~~-			8437,~~950~~878
Loans and Obligations		~~31,427~~-			6031,~~559~~427
Total Long-Term Liabilities		69,305			145,509
Total Liabilities		1,928,573			3,215,610
Total Liabilities		3,215,610			1,632,031
Commitments and Contingencies (Note 11)		-			-
Commitment and Contingencies (Note 12)		-			-
Stockholders’ Equity
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 shares issued and outstanding as of March 31, 2025 and, 2024		1,000			1,000
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of March 31, 2026, and March 31, 2025, respectively		1,000			1,000
Common stock, par value $0.001 per share, 350,000,000 shares authorized; 295,347,903 and 309,981,819 shares issued and 294,302,607 and 309,981,819 shares outstanding as of March 31, 2025, and March 31, 2024, respectively		295,348			309,982
Common stock, par value $0.001 per share, 300,000,000 shares authorized; 291,324,607 shares issued and outstanding as of March 31, 2026, and 295,347,903 issued and 294,302,607 outstanding as of March 31, 2025		291,324			295,348
Additional Paid in Capital		3130,~~480~~826,~~143~~352			31,~~593~~480,~~399~~143
Accumulated Deficit		(2724,~~738~~108,~~975~~199	)		(2927,~~655~~738,~~076~~975	)
Treasury Stock, at cost (1,045,296 Shares)		(186,404	)		—
Treasury Stock, at cost (0 and 1,045,296 shares as of March 31, 2026, and March 31, 2025, respectively)		-			(186,405	)
Total Equity		3,851,111			2,249,305
Total Stockholders’ Equity		7,010,477			3,851,111
TOTAL LIABILITIES AND EQUITY	$	7,066,721		$	3,881,336
Non-Controlling Interest		30,287			-
Total Equity		7,040,764			3,851,111
TOTAL LIABILITIES AND EQUITY	$	8,969,337		$	7,066,721

The accompanying notes are an integral part of these consolidated financial statements.

F-3

EARTH SCIENCE TECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR YEARS ENDED MARCH 31, ~~2025~~2026, AND ~~2024~~2025

	2025			2024
	2026			2025
Revenue	$	3335,~~117~~695,~~624~~614		$	1133,~~953~~117,~~635~~624
Cost of Goods Sold		810,~~817~~207,~~488~~557			48,~~125~~817,~~139~~488
Gross Profit		2425,~~300~~488,~~136~~057			724,~~828~~300,~~496~~136
Expenses
Salaries Expense		1413,~~115~~776,~~643~~033			414,~~358~~115,~~917~~643
Selling general and administrative expenses		43,~~154~~571,~~838~~448			~~166~~4,~~976~~154,838
Bank charges		1,~~066~~006,~~577~~026			~~422~~1,~~970~~066,577
Advertising & marketing		~~836~~2,~~860~~840,553			25836,~~283~~860
Legal and professional fees		~~305~~221,~~932~~179			1305,~~774,182~~932
Insurance		~~180~~168,~~281~~353			5180,~~363~~281
Depreciation and amortization		151,655			149,749
Operating lease cost		180,753			98,434
Utilities		40,392			15,368
Depreciation and amortization		284,396			53,951
Rent expense		—			10,797
Utilities		130,790			39,661
Miscellaneous		—			6,542
Total Expenses	$	22,179,531		$	20,852,178
Total Expenses	$	20,852,178		$	6,936,147
Other income (expense)
Dividend income		9,123			—
Dividend and interest income		15,458			9,141
Interest earned		17			—
Net realized gain on sale of investments		671,528			300,162
Net realized gain on sale of investments		300,162			—
Unrealized Gain (Loss) on fair value changes of investments		(957,118	)		(365,661	)
Unrealized Gain (Loss) on fair value changes of investments		(365,661	)		—
Other		67,194			-
Interest Expense		(2116,~~189~~327	)		(6721,~~207~~189	)
Net Income before taxes		3,~~370~~089,~~410~~261			~~825~~3,~~142~~370,411
Income Taxes		~~116~~(511,~~776~~676	)		13116,~~003~~776
Net Income	$	3,~~253~~600,~~635~~937		$	~~812~~3,~~139~~253,635
Earnings per common share-Basic and Diluted	$	0.011		$	0.003
Net Income/(Loss) attributed to non-controlling interest		(29,839	)		-
Weighted average number of shares outstanding- Basic and Diluted		303,521,458			309,687,386
Net Income available to common stockholders’		3,630,776			3,253,635
Earnings per common share-Basic and Diluted	$	0.012		$	0.011
Weighted average number of shares outstanding- Basic and Diluted		293,069,803			303,521,458

The accompanying notes are an integral part of these consolidated financial statements.

F-4

EARTH SCIENCE TECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR YEARS ENDING MARCH 31, ~~2025~~2026, AND ~~2024~~2025

Description	Shares			Amount			Shares		Amount		Capital			Deficit			~~Stock~~NCI			~~Total~~Stock			Total
	Common Stock						Preferred Stock				Additional paid in			Accumulated			~~Treasury~~			Treasury
Description	Shares			Amount			Shares		Amount		Capital			Deficit			~~Stock~~NCI			~~Total~~Stock			Total
Balance at March 31, 2024		309,981,819		$	309,982			1,000,000	$	1,000	$	31,593,399		$	(29,655,076	)		-		$	2,249,305
Balance at March 31, 2025		295,347,903		$	295,348			1,000,000	$	1,000	$	31,480,143		$	(27,738,975	)		-		$	(186,405	)	$	3,851,111
Repurchase of common stock		(14,633,916	)		(14,635	)		-		-		(113,256	)		(1,337,534	)		-			(1,465,425	)
Balance		295,347,903		$	295,348			1,000,000	$	1,000	$	31,480,143		$	(27,738,975	)		-		$	(186,405	)	$	3,851,111
Treasury Stock		-			-			-		-		-			-			(186,404	)		(186,404	)
Repurchase of common stock		-								-		-			-			-			(471,410	)		(471,410	)
Net Income		-			-					-		-			3,253,635			-			3,253,635
Retirement Treasury Stock		(4,023,296	)		(4,024	)		-		-		(653,791	)		-			-			657,815			-
Balance at March 31, 2025		295,347,903		$	295,347			1,000,000	$	1,000	$	31,480,143		$	(27,738,975	)	$	(186,404	)	$	3,851,111
Acquisition of subsidiaries		-			-			-		-		-			-			60,126			-			60,126
Net Income		-			-			-		-		-			3,630,776			(29,839	)		-			3,600,937
Balance at March 31, 2026		291,324,607		$	291,324			1,000,000		1,000	$	30,826,352		$	(24,108,199		$	30,287		$	-		$	7,040,764
Balance		291,324,607		$	291,324			1,000,000		1,000	$	30,826,352		$	(24,108,199		$	30,287		$	-		$	7,040,764

Description	Shares			Amount			Shares		Amount		Capital			Deficit			Stock			Total
	Common Stock						Preferred Stock				Additional paid in			Accumulated			Treasury
Description	Shares			Amount			Shares		Amount		Capital			Deficit			Stock			Total
Balance at March 31, 2023		282,611,083		$	282,612			1,000,000	$	1,000	$	31,303,138		$	(30,467,215	)		-		$	1,119,535
Balance at March 31, 2024		309,981,819		$	309,982			1,000,000	$	1,000	$	31,593,399		$	(29,655,076	)		-		$	2,249,305
Balance		~~282~~309,~~611~~981,~~083~~819		$	~~282~~309,~~612~~982			1,000,000	$	1,000	$	31,~~303~~593,~~138~~399		$	(3029,~~467~~655,~~215~~076	)		-		$	12,~~119~~249,~~535~~305
Common stock issued for cash		18,864,423			18,864			-		-		91,467			-			-			110,331
Repurchase of common stock		(14,633,916	)		(14,635	)		-		-		(113,256	)		(1,337,534	)		-			(1,465,425	)
Stock-based compensation		300,000			300			-		-		-			-			-			300
Treasury Stock		-			-			-		-		-			-			(186,405	)		(186,404	)
Repurchase of common stock		(5,200,000	)		(5,200	)		-		-		(172,800	)		-			-			(178,000	)
Net Income															3,253,635			-			3,253,635
Common stock issued for conversion of debt		13,406,313			13,406			-		-		371,594			-			-			385,000
Balance at March 31, 2025		295,347,903		$	295,347			1,000,000	$	1,000	$	31,480,143		$	(27,738,975	)	$	(186,405	)	$	3,851,111
Net Income		-			-			-		-		-			812,139			-			812,139
Balance		295,347,903		$	295,347			1,000,000	$	1,000	$	31,480,143		$	(27,738,975	)	$	(186,405	)	$	3,851,111
Balance at March 31, 2024		309,981,819		$	309,982			1,000,000		1,000	$	31,593,399		$	(29,655,076	)		-		$	2,249,305
Balance		309,981,819		$	309,982			1,000,000		1,000	$	31,593,399		$	(29,655,076	)		-		$	2,249,305

The accompanying notes are an integral part of these consolidated financial statements.

F-5

EARTH SCIENCE TECH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR YEARS ENDED MARCH 31, ~~2025~~2026, AND ~~2024~~2025

	2025			2024
	2026			2025
Cash flows from operating activities:
Net Income	$	3,~~253~~600,~~635~~937		$	~~812~~3,~~139~~253,635
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		~~151~~284,~~654~~396			~~149~~53,~~749~~951
Stock based compensation		—			~~300~~-
Unrealized loss on investments		~~365~~957,~~661~~118			—365,661
Realized gain on sale of investments		(~~300~~671,~~162~~528	)		—(300,162	)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable		~~106~~(226,~~359~~990	)		~~(235~~106,~~423~~359	)
Deposits		(328,756	)		(9,352	)
Prepaid expenses and other current assets		(120,843	)		(349,485	)
Prepaid expenses and other current assets		(20,729	)		—
Inventory		(141,516	)		(188,200	)
Inventory		(188,200	)		(305,478	)
Deferred tax asset		(772,294	)
Other current liabilities
Accounts payable and accrued expenses and other		(968,417	)		1,430,631
Lease liability, net		(96,003	)		(73,870	)
Net cash provided by operating activities		1,940,863			4,372,390
Accounts payable and accrued expenses		1,428,932			868,176
Net cash provided by operating activities		4,372,390			1,206,241
Cash flows from investing activities:
Purchases of property and equipment and intangibles		(753,165	)		(26,520	)
Purchases of property and equipment, intangibles and long-lived assets available for sale		(756,619	)		(753,165	)
Purchase of investments		(47,~~312~~574,~~675~~996	)		—(4,312,675	)
Sale of investments		36,~~601~~574,~~738~~804			—3,601,738
Cash used for assets acquisition, net of cash acquired		(~~417~~147,~~248~~566	)		(417,248	)
Net cash used in investing activities		(1,~~881~~904,~~350~~377	)		(261,~~520~~881,350	)
Cash flows from financing activities:
Proceeds from issuance of common stock		—			110,331
Payments on loans and obligations		(241,507	)		(429,131	)
Payments on loans and obligations		(429,131	)		(450,217	)
Proceeds from loan payable		-			179,488
Proceeds from loan payable		179,488			—
Repurchase of common stock		(471,410	)		(1,465,890	)
Repurchase of common stock		(1,465,890	)		(178,000	)
Net Cash used in financing activities		(712,917	)		(1,715,533	)
Net Cash used in financing activities		(1,715,533	)		(517,886	)
Net increase (decrease) in cash and cash equivalents		(676,431	)		775,507
Net increase in cash and cash equivalents		775,507			661,835
Cash and cash equivalents at beginning of the year		1,473,228			697,721
Cash and cash equivalents at beginning of the year		697,721			35,756
Cash and cash equivalents at end of the year	$	796,797		$	1,473,228
Cash and cash equivalents at end of the year	$	1,473,228		$	697,721
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest	$	2116,~~189~~327		$	6721,~~207~~189
Cash paid for income taxes	$	28152,~~319~~599		$	-28,319
Non-Cash Transactions		-			-
Initial recognition of right of use asset	$	~~100~~104,~~294~~906		$	-100,294
Common stock issued on conversion of notes payable	$	-		$	385,000

The accompanying notes are an integral part of these consolidated financial statements.

F-6

NOTE 1- — ORGANIZATION AND NATURE OF ~~OPERATIONS~~OPERATION

~~Earth~~ETST ~~Science~~operates ~~Tech,~~as ~~Inc.~~a ~~(“ETST”~~diversified )holding ~~was~~company ~~incorporated~~focused ~~under~~on the ~~laws~~health ofand ~~the~~wellness ~~State~~sector. ofThe ~~Nevada~~Company’s onprincipal ~~April~~operating ~~23, 2010, and subsequently redomiciled~~strategy is to ~~the~~build ~~State~~a ofvertically ~~Florida~~integrated onhealthcare ~~June~~platform ~~27,~~that ~~2022.~~combines Ascompounding ofpharmacy ~~November~~operations, 8telemedicine platforms, ~~2022~~clinical support, ~~ETST~~and ~~operates~~direct-to-patient asfulfillment. aThe ~~holding~~Company’s ~~company~~healthcare ~~focused~~operations onare ~~acquisitions~~supported by investments in ~~the~~real ~~health~~estate and asset management activities and ~~wellness~~a ~~sector~~consumer products business.

The core of the Company’s ~~current~~value ~~operations~~proposition ~~include~~is ~~compounding~~the ~~pharmaceuticals,~~seamless ~~telemedicine~~integration ~~and~~of ~~real~~patient ~~estate~~care, ~~development~~from ~~through~~consultation ~~its~~to ~~wholly owned subsidiaries: RxCompoundStore~~fulfillment.~~com,~~ ~~LLC~~This ~~(“RxCompound”), Peaks Curative, LLC (“Peaks”), Avenvi, LLC (“Avenvi”),~~is ~~Mister~~achieved ~~Meds,~~through ~~LLC (“Mister Meds”), and Earth Science Foundation, Inc. (“ESF”). Subsequent to~~ the ~~reporting~~synergy ~~period, the Company acquired 100%~~ of ~~Las~~specialized ~~Villas Health Care, Inc~~subsidiaries. ~~(“Villas”),~~The ~~DOConsultations,~~Company’s ~~LLC~~activities ~~(“DOC”), and an 80% interest in MagneChef (“Magne”).~~include:

~~RxCompound,~~Health ~~based in Miami, Florida, is a fully licensed compounding pharmacy authorized to fulfill prescriptions in the following states~~ and territories: Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, Utah, Wisconsin and Puerto Rico. RxCompound is actively pursuing licensure in the remaining U.S. states.wellness

~~Peaks is~~● aRxCompoundStore.com: ~~telemedicine~~Multi-state ~~referral~~(Florida ~~platform~~based) ~~offering~~sterile/non-sterile ~~asynchronous~~compounding ~~consultations~~ for ~~Peaks-branded~~specialized ~~compounded~~therapies; ~~medications~~providers ~~prepared~~and atpatients ~~RxCompound and~~needing ~~Mister~~access ~~Meds~~beyond ~~pharmacies~~retail chains. ~~The~~● ~~platform~~Mister ~~operates~~Meds: inMulti-state ~~states~~(Texas ~~where~~based) ~~either~~sterile/hazardous ofcompounding ~~these~~center; ~~two~~Texas ~~pharmacies~~patients ~~are~~and ~~licensed.~~referring ~~Through~~clinicians; ~~the~~fast ~~development of~~TX ~~its~~dispensing ~~own~~and ~~healthcare~~hub ~~provider~~for ~~network,~~nearby ~~MyOnlineConsultation~~states.~~com,~~ ~~and~~● ~~ongoing~~Peaks ~~licensure~~Curative: ~~expansion~~Frictionless ~~for~~asynchronous ~~both~~consults funneling to licensed pharmacies,; ~~Peaks~~digitally ~~aims~~engaged ~~to offer~~patients ~~services~~seeking ~~nationwide~~convenience. In● ~~addition,~~DOConsultations: ~~the~~Virtual ~~company~~care ~~has~~brand ~~recently~~for ~~expanded~~home-based ~~into~~therapies; ~~the~~patients ~~veterinary~~wanting ~~market~~guided ~~through~~telehealth ~~the~~with ~~acquisition~~ongoing offollow-up. ~~Zoolzy~~● Villas Health Care: Localized in-person wellness clinic designed to expand patient access.~~com.~~

~~Avenvi~~Asset isManagement ~~a diversified real estate company engaged in development, asset management,~~ and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company’s ongoing $5 million share repurchase program.Other

	●	Avenvi: A diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company’s ongoing $10 million share repurchase program.

	●	MagneChef: A direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property.

Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Villas’ expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. Villas combines compassionate, personalized care with clear, trustworthy education.

DOC was founded with a mission to modernize the availability and delivery of home-based therapies. DOC provides consultation to develop personalized a medication plans tailored to each customer’s health and wellness goals.

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

F-7

Principles of consolidation

The accompanying consolidated financial statements include all the accounts of the Earth Science Tech, Inc. and its wholly owned subsidiaries ~~RxCompoundstore~~RxCompound, Peaks, Avenvi, ~~and~~ Mister Meds, Villas Health, DOConsultations, and majority owned subsidiary Magnechef (collectively, the “Company”). All intercompany transactions have been eliminated during consolidation.

Use of estimates and assumptions

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas requiring ~~significant~~material estimates are impairment of goodwill, provision for taxation, useful ~~life~~lives of depreciable assets, useful ~~life~~lives of intangible assets, ~~contingencies~~recoverability of inventory and long-lived assets available for sale, commitments and contingencies, and going concern assessment. The estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from those estimates.

F-7

Impairment of Long-Lived Assets

The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is assessed based on the estimated undiscounted cash flows expected to result from the use and eventual disposition of the assets. If the carrying amount exceeds the asset’s fair value, an impairment loss is recognized in the amount of the excess. No impairment losses were recognized for the years ended March 31, ~~2025~~2026, and ~~2024~~2025.

Cash and cash equivalents.

Cash and cash equivalents include all highly liquid ~~debt~~financial instruments with original maturities of three months or less, As of March 31, ~~2025,~~ 2026, the Company’~~scash~~s cash balance exceeded federally insured limits by approximately $~~607~~142,~~620~~450. The Company maintains its cash with high-credit-quality financial institutions and has not experienced any losses in such accounts. Management believes the Company is not exposed to significant credit risk with respect to these balances.

Accounts Receivable.

Accounts receivable are carried at their contractual amounts, less an estimated allowance for credit losses. Management estimates the allowance for credit losses using a loss-rate approach based on historical loss information, adjusted for management’s expectations about current and future economic conditions, as the basis to determine expected credit losses. Management exercises significant judgment in determining expected credit losses. Key inputs include macroeconomic factors, industry trends, the creditworthiness of counterparties, historical experience, the financial conditions of the customers, and the amount and age of past due accounts. Management believes that the composition of receivables at year-end is consistent with historical conditions as credit terms and practices and the client base has not changed significantly. Receivables are considered past due if full payment is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only after all collection attempts have been exhausted. As of March 31, ~~2025~~2026, and ~~2024~~2025, the Company had not recorded an allowance for credit losses, as management determined that no reserve was necessary based on its assessment of the collectability of outstanding balances and the credit quality of its customers.

Revenue recognition

In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, the Company recognizes revenue when it satisfies performance obligations, by transferring promised goods or services to customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for fulfilling those performance obligations. Revenue for product sales is recognized at point of sale ori.e. upon shipment,. ~~depending~~Revenue onfor ~~the~~services ~~terms~~is recognized upon completion of the ~~arrangement~~contracted service i.e. in-person and telemedical doctor consultations. There are no material contract assets or contract liabilities ~~and therefore no unsatisfied performance obligations~~.

~~F-8~~Equity securities

Equity Investments at fair value

The Company accounts for its equity securities in accordance with ASC 321, Investments – Equity Securities, as amended by ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities. Equity securities with readily determinable fair values are measured at fair value, with changes in fair value recognized in earnings in the period in which they occur.

~~The following summarizes the aggregate cost and fair value of the Company’s equity securities as of March 31, 2025 and 2024:~~F-8

The following summarizes the aggregate cost and fair value of the Company’s equity securities as of March 31, 2026, and 2025:

SCHEDULE OF EQUITY INVESTMENTS

	2025			2024
	For the Years Ending March 31,
Cost Basis	$	1,011,099			-
	2026			2025
Unrealized gain/(loss)		(365,661	)		-
Cost Basis	$	2,317,158			1,011,099
Equity securities - Fair value	$	645,438			-
Unrealized loss		(957,118	)		(365,661	)
Equity securities - Fair value	$	1,360,040			645,438

Disaggregated Revenue

In accordance with ASC 606, the Company disaggregates revenue from contracts with customers by category ~~— core and non-core -~~ as it believes it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

The Company’s disaggregated revenue by category is as follows:

SCHEDULE OF DISAGGREGATED REVENUE

	2025		2024
	2026		2025
	For the Years Ending March 31,
	2025		2024
	2026		2025
Core:
Sale of pharmaceutical products and medical consultations	$	32,908,881	$	30,027,373
Sale of Pharmaceutical products – RxCompound	$	29,492,724	$	11,924,804
Shipping and handling		2,485,908		3,090,251
Sale of Pharmaceutical products –Peaks		534,649		28,831
Other		300,825		-
Total core revenue, net	$	30,027,373	$	11,953,635
Total revenue, net	$	35,695,614	$	33,117,624
Non-Core:
Shipping Income	$	3,090,251	$	-
Total revenue, net	$	33,117,624	$	11,953,635

During the years ended March 31, 2025 and 2024, the Company had a net realized gain on sales of investments of $300,162 and $0, and dividend income of $9,123 and $0. These amounts are not included in revenue from contracts with customers and are classified separately in other income.

As of March 31, 2025, the Company had three significant customers, accounting for approximately 7%, 10% and 9% of revenue. Total accounts receivable balances for these three customers were as follows:

	2025		2024
	2026		2025
	For the Years Ending March 31,
	As of March 31,
	2025		2024
	2026		2025
Accounts Receivables	$	129,064	$	235,423
Accounts Receivables, Net	$	356,054	$	129,064

F-9

Inventory

Inventory is stated at the lower of cost or ~~market~~net realizable value. Cost is determined using the first-in, first-out (FIFO) method. ~~Inventory consists primarily of finished goods.~~

The Company evaluates inventory for excess and obsolescence based on factors such as current inventory levels, estimated product life cycles, historical and forecasted customer demand, and input from the product development team. When necessary, a reserve is recorded to reduce the carrying value of inventory to its estimated net realizable value. These estimates and assumptions are reviewed at least annually and updated as needed based on the Company’s business plans and market conditions.

~~Cost~~Long oflived ~~Goods~~asset ~~Sold~~available for sale

~~Components~~As of ~~cost~~March of31, ~~goods~~2026, ~~sold~~the ~~include~~Company ~~product~~classified ~~costs,~~a ~~consumables~~residential property as a long-lived asset held for sale with a carrying value of $371,684, which ~~shipping~~is ~~costs~~presented towithin ~~customers~~current ~~and~~assets ~~any~~in ~~inventory~~the ~~adjustments~~accompanying consolidated balance sheet.

Prior to year-end, management committed to a plan to sell the property, which was available for immediate sale in its present condition.

F-9

Subsequent to March 31, 2026, the Company entered into a binding agreement to sell the property with an expected gain on the sale.

Cost of goods sold

Components of cost of goods sold include product costs, consumables, testing and shipping costs to customers and any inventory adjustments.

Shipping and Handling

Costs incurred by the Company for shipping and handling are included in costs of ~~goods sold~~revenue.

Salaries Expense

Salaries expense is the aggregate cost associated with all employees, including named executives, pharmacists, administrative staff and technicians involved in fulfillment.

Income taxes

The Company accounts for income taxes under ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Earnings per share

The Company follows ASC 260 to account for earnings per share. Basic earnings per common share calculations are determined by dividing net results from operations by the weighted average number of shares of common stock outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted. Diluted earnings per share is calculated using the weighted average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, if any, using the treasury stock method.

For the years ended March 31, ~~2025~~2026, and ~~2024~~2025, basic and diluted earnings per share are the same because the Company had no potentially dilutive securities outstanding during those periods.

F-10

Goodwill

Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Goodwill is reviewed for impairment on an annual basis, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may be impaired. In conducting its annual impairment test, the Company first reviews qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If factors indicate that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment, and the fair value of the reporting unit is determined ~~by analyzing the expected present value of future cash flows~~. If the carrying value of the reporting unit ~~continues~~exceeds ~~to exceed its~~ fair value, ~~the fair value of the reporting unit’s goodwill is calculated and~~ an impairment loss equal to the excess is recorded.

~~Stock Based Compensation~~F-10

The Company applies the fair value method of ASC 718, Compensation-Stock Compensation, in accounting for its stock-based compensation. These standards state that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period, if any. The Company uses the Black-Scholes option pricing model to determine the fair value of its stock, stock option and warrant issuance. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price, as well as assumptions regarding a few complex and subjective variables. These variables include the Company’s expected stock price, volatility over the term of the awards, actual employee exercise behaviors, risk-free interest rate and expected dividends. No stock-based commitments were outstanding as of March 31, 2025, and 2024.

Fair Value

FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories:

Level 1 — Quoted market prices for identical assets or liabilities in active markets or observable inputs,

Level 2 — Significant other observable inputs that can be corroborated by observable market data; and

Level 3 — Significant unobservable inputs that cannot be corroborated by observable market data.

~~The~~As ~~carrying~~of ~~amounts~~March of31, 2026, and 2025, all the Company’s ~~financial~~investments ~~instruments,~~were ~~such~~classified as ~~cash,~~Level ~~accounts~~1 ~~receivable, accounts payable~~ and ~~other~~were ~~liabilities, approximate~~measured at fair value ~~because~~using ofquoted market ~~the~~prices ~~short-term~~in ~~nature~~active ~~of these items~~markets.

AsThe fair value of the Company’s debt approximates its carrying value as of March 31, ~~2025,~~2026. ~~all~~Factors ofthat the Company’s ~~investments~~considered ~~were~~when estimating ~~classified~~the asfair ~~Level~~value 1of ~~and~~its ~~were~~debt ~~measured~~included atmarket ~~fair~~conditions, ~~value~~liquidity ~~using~~levels ~~quoted~~in the private placement market ~~prices~~, variability in ~~active~~pricing from ~~markets~~multiple lenders and terms of debt.

The fair value of the Company’s debt approximates its carrying value as of March 31, 2025 and 2024. Factors that the Company considered when estimating the fair value of its debt included market conditions, liquidity levels in the private placement market, variability in pricing from multiple lenders and terms of debt.

Property and equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation on property and equipment is charged using a straight-line method over the estimated useful life of 5 years. An estimated useful life of 20 years is used for buildings.

F-11

Recently issued accounting pronouncements

In ~~June 2016~~2025, the FASB issued ASU ~~No. 2016~~2025-1306, ~~Financial~~Intangibles—Goodwill ~~Instruments~~and –Other—Internal-Use ~~Credit~~Software ~~Losses~~ (~~Topic~~Subtopic ~~326~~350-40),: ~~Measurement~~Targeted ofImprovements to ~~Credit~~the ~~Losses~~Accounting ~~on Financial~~for ~~Instruments~~Internal-Use Software, aswhich ~~modified~~updates bythe ~~FASB~~guidance ~~ASU~~for ~~No.~~capitalizing ~~2019~~internal-10use ~~and~~software ~~other~~costs ~~subsequently~~by ~~issued~~introducing ~~related~~a principles-based ~~ASUs.~~recognition ~~The~~threshold ~~amendments~~that infocuses ~~this~~on ~~Update affect~~management ~~loans,~~authorization ~~debt~~and ~~securities,~~committed ~~trade~~funding ~~receivables,~~ and ~~any~~the ~~other~~probability ~~financial~~of ~~assets~~project completion ~~that~~and ~~have~~intended ~~the~~use, ~~contractual~~with ~~right~~explicit toconsideration ~~receive~~of ~~cash~~development uncertainty. The ASU ~~requires~~also anenhances ~~entity~~related todisclosures ~~recognize~~for ~~expected~~capitalized software ~~credit~~and ~~losses~~does ~~rather~~not ~~than~~change ~~incurred~~the ~~losses~~guidance for ~~financial~~software ~~assets.~~to ~~The~~be ~~amendments~~sold, inleased, ~~this~~or ~~Update are~~otherwise marketed. ASU 2025-06 is effective for fiscal years beginning after December 15, ~~2022~~2027, ~~including~~and for interim periods within those fiscal years., ~~The~~with ~~Company~~early ~~adopted~~adoption permitted and multiple ~~this~~transition ~~new~~options ~~guidance~~available. ~~effective~~The ~~January~~Company 1,has ~~2023~~not ~~utilizing~~early ~~the~~adopted ~~modified~~this ~~retrospective~~guidance ~~transition~~and ~~method.~~is ~~The~~evaluating ~~adoption~~its ofimpact ~~this~~on ~~standard~~capitalization ~~did~~policies, ~~not~~expense ~~have~~recognition atiming, ~~material~~and ~~impact~~related ondisclosures; the ~~Company’s~~impact ~~consolidated~~is ~~financial~~not ~~statements,~~expected ~~but~~to ~~did~~be ~~change~~material ~~how~~to the ~~allowance~~consolidated ~~for~~financial ~~credit losses~~statements isbut ~~determined~~will require additional disclosures.

In 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income (Topic 220): Expense Disaggregation Disclosures, which requires public business entities to present in the notes a tabular disaggregation of each relevant income-statement expense caption within continuing operations into specified natural categories (including purchases of inventory, employee compensation, depreciation, intangible-asset amortization, and depletion/DD&A), with reconciling “other” and related narrative descriptions, and to disclose total selling expenses and the Company’s definition of “selling expenses.” The ASU is disclosure-only and does not change recognition, measurement, or presentation on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within those fiscal years beginning after December 15, 2027, with early adoption permitted. The Company has not early adopted this guidance and is evaluating its impact, which is not expected to be material to the consolidated financial statements but will result in additional footnote disclosures.

F-11

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose significant segment expenses and other segment items on an interim and annual basis and provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. The ASU does not change how a public entity identifies its operating segments, aggregates them, or applies the quantitative threshold to determine its reportable segments. The new disclosure requirements are also applicable to entities that account and report as a single operating segment entity. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. The Company adopted the guidance for the annual reporting period ended December 31, 2024. There was no impact on the Company’s reportable segments identified.

Intangible assets

Intangible assets consist of ~~the~~a ~~Peaks~~ telemedicine platform, ~~the Holding Company’s~~ web domains, ~~and~~patents, ~~Mister~~designs ~~Meds~~and ~~LLC’s~~ software ~~and domain~~. These intangible assets are considered to have finite useful lives and are amortized on a straight-line basis over an estimated useful ~~life~~lives ofranging from five years to twenty years.

The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If such indicators exist, the Company compares the carrying amount of the asset to the expected undiscounted future cash flows. An impairment loss is recognized if the carrying amount exceeds the asset’s fair value. No impairment losses were recognized for the years ended March 31, ~~2025~~2026, and ~~2024~~2025.

NOTE 3- INVENTORY

As of March 31, ~~2025~~2026, and March 31, ~~2024~~2025, inventory consisted of raw materials and finished goods. Given the ~~inventory~~nature ~~reserves~~of ~~were~~our ~~not~~pharmaceutical products, ~~material~~and the storage protocols associated with inventories compounding activities occur at the time of, or shortly before receipt of customer orders and shipment of finished goods.

~~SCHEDULE~~As OFof ~~INVENTORIES~~March 31, 2026, and 2025, the Company’s inventory consisted of raw materials totaling $612,824 and $411,810, respectively, and finished goods totaling $69,235 and $92,128, respectively.

	2025		2024
	As of March 31,
	2025		2024
Raw materials	$	411,810	$	266,776
Finished goods		92,128		48,962
Inventory	$	503,938	$	315,738

F-12

NOTE 4 – PROPERTY AND EQUIPMENT, NET

SCHEDULE OF PROPERTY AND EQUIPMENT

	2025			2024
	2026			2025
	As of March 31,
	2025			2024
	2026			2025
Land	$	~~281~~305,~~209~~651		$	-281,209
Building		329,647			-329,647
Equipment		~~860~~1,~~736~~194,786			~~176~~860,~~602~~736
Property and Equipment, cost		~~860~~1,~~736~~194,786			~~176~~860,~~602~~736
Less: Accumulated depreciation		(87312,~~482~~196	)		(4187,~~250~~482	)
Property and Equipment, Net	$	1,~~384~~517,~~110~~888		$	~~135~~1,~~352~~384,110

Depreciation expense for the years ended March 31, ~~2025~~2026, and March 31, ~~2024~~2025, were $43219,~~998~~862 and $3443,~~381~~998 respectively.

NOTE 5- LEASES

The Company treats a contract as a lease when the contract conveys the right to use a physically distinct asset for a period in exchange for consideration, or the Company directs the use of the asset and obtains substantially all the economic benefits of the asset. These leases are recorded as right-of-use (“ROU”) assets and lease obligation liabilities for leases with terms greater than 12 months. ROU assets represent the Company’s right to use an underlying asset for the entirety of the lease term. Lease liabilities represent the Company’s obligation to make payments over the life of the lease. A ROU asset and a lease liability are recognized at commencement of the lease based on the present value of the lease payments over the life of the lease. Initial direct costs are included as part of the ROU asset upon commencement of the lease. Since the interest rate implicit in a lease is generally not readily determinable for the operating leases, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar lease term to obtain an asset of similar value.

F-12

The Company reviews the impairment of ROU assets consistent with the approach applied to the Company’s other long-lived assets, assessing recoverability when events or changes in circumstances indicate the carrying value may not be recoverable. The Company elected the practical expedient to exclude short-term leases (leases with original terms of 12 months or less) from ROU asset and lease liability accounts. The Company has elected not to apply the other transition practical expedients available under ASC 842.

The Company’s leases are classified as operating leases. Lease expense for operating leases is recognized on a straight-line basis over the lease term.

F-13

Supplemental balance sheet information related to leases were as follows:

	2025		2024
	2026		2025
	As of March 31,
	2025		2024
	2026		2025
Assets
Right of use asset, net	$	~~172~~95,~~429~~317	$	~~156~~172,~~517~~429
Operating lease liabilities
Current		~~121~~96,~~851~~206		70121,~~487~~851
Non-current		~~37,878~~-		8437,~~950~~878
Total Lease Liabilities	$	~~159~~96,~~729~~206	$	~~155~~159,~~437~~729

The components of lease cost were as follows:

SCHEDULE OF LEASE COST

	2025		2024
	2026		2025
	For the Years Ending March 31,
	2025		2024
	2026		2025
Operating lease cost	$	90180,~~650~~753	$	~~108~~90,~~533~~650
Variable lease cost		7195,~~784~~270		57,~~595~~784
Sublease income		-		-
Total lease cost	$	98376,~~434~~023	$	~~114~~98,~~128~~434

F-13

Lease term and discount rate were as follows:

SCHEDULE LEASE TERM AND DISCOUNT RATE

	For the Years Ending March 31,
	2025			2024
	2026			2025
Weighted average remaining lease term - Operating leases		1.5 years			21.255 years
Weighted average discount rate - Operating leases		3	%		3	%

The following table presents the future minimum lease payments under non-cancelable operating leases as of March 31, ~~2025~~2026:

Year ended March 31	Operating Leases
2026	$	125,072
2027	$	92,697
2027		38,317
2028		4,566
Total		163,389
Total future minimum lease payments		97,263
Less: imputed interest		3(1,~~660~~057	)
Present value of lease payment	$	159,729
Present value of future minimum lease payments	$	96,206

F-14

NOTE 6 - INTANGIBLE ASSETS

Intangible assets consisted of the following:

SCHEDULE OF INTANGIBLE ASSETS

	2025			2024
	2026			2025
	As of March 31,
	2025			2024
	2026			2025
Telemedicine Platform	$	17,806		$	17,806
Web Domain		41,386			19,323
Web Domains		53,704			41,386
Software		56,334			-
Internal use software		138,086			56,334
Gross Balance		56,334			-
Patents and Designs		89,678			-
Accumulated Amortization		(18,641	)		(8,688	)
Gross Balance		89,678			-
Net Balance		96,885			28,441
Accumulated Amortization		(91,104	)		(18,641	)
Amortization expense	$	9,953		$	6,835
Net Balance		208,170			96,885
Amortization expense	$	64,534		$	9,953

NOTE 7- GOODWILL

Goodwill was ~~recorded~~recognized in connection with the ~~acquisition of RxCompoundStore.com, LLC and Peaks. On November 08, 2022, the~~ Company’s ~~acquired~~acquisitions ~~100%~~ of ~~the outstanding equity interest of~~ RxCompoundStore~~.com~~, LLC ~~and~~(“RxCompound, Peaks ~~Curative~~, ~~LLC~~Las ~~in exchange for shares~~Villas, DOCConsultations, and ~~recognized Goodwill as part of the purchase price allocation~~MagneChef.

~~NOTE 8~~F- ~~ACCRUED EXPENSES AND OTHER PAYABLES~~14

On November 8, 2022, the Company acquired 100% of the outstanding equity interests of RxCompound and Peaks in exchange for shares of the Company’s common stock. These transactions were accounted for as business combinations in accordance with ASC 805, and goodwill was recorded as part of the purchase price allocation.

On April 1, 2026, the Company acquired 100% of the outstanding equity interests of Las Villas and DOConsultations, and 80% of the outstanding equity interests of MagneChef. These acquisitions were also accounted for as business combinations, and goodwill was recognized for each transaction based on the excess of consideration transferred over the fair value of the identifiable net assets acquired.

NOTE 8- ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other payables consisted of the following:

	2025		2024
	2026		2025
	As of March 31,
	2025		2024
	2026		2025
Officer compensation		1,812,680		666,883
Payroll accrual		508,456		2,067,044
Merchant fees		97,965		68,891
Other current liabilities		445,540		166,551
Payroll accrual		254,364		68,488
Income tax payable		196,446		88,427
Credit card payable		68,586		37,456
Total	$	1,150,442	$	2,322,022
Income-tax payable		88,427		13,001
Total Accrued Expenses	$	2,322,022	$	854,719

F-15

NOTE 9 – DEBT

~~Loans~~The ~~and~~Company ~~Obligations~~repaid ~~consists~~in offull anits ~~equipment~~long-term ~~loan~~debt ~~bearing~~- ~~interest~~other atduring ~~5.28%~~the ~~per~~year ~~annum~~ended ~~and matures~~ March 1231, ~~2027~~2026. ~~Scheduled~~Prior ~~principal~~to ~~payments are~~repayment, asthe ~~follows:~~outstanding ~~$31,010~~balance ~~due~~consisted of ~~during~~an ~~the~~equipment ~~year~~loan ~~ended~~bearing ~~March~~interest ~~31,~~at ~~2026~~5.28% ~~and~~per ~~$31~~annum,~~009~~ ~~due~~with ~~during~~a ~~year~~contractual ~~ended~~maturity date of March 3112, 2027. Interest expense ~~for~~related to this loan was de minimis for each of the years ended March 31, ~~2025 and 2024 was $3~~2026,~~274~~ and ~~$4,125~~2025.

~~Short~~The Company had no outstanding short-term business ~~loan~~loans ~~represents~~as of March 31, 2026. From time to time, the Company utilizes a margin loan ~~from~~facility with Charles Schwab, ~~bearing~~which bears interest ofat ~~11.075~~a floating rate, which was approximately 10% per annum as of March 31, 2026. ~~The~~Borrowings under ~~loan~~this isfacility are generally repaid from the proceeds of stock and option ~~salesTotal~~transactions ~~interest~~and ~~expense~~are ~~for~~collateralized by the ~~years~~Company’s investments ~~ending~~in ~~March~~equity ~~31, 2025 and 2024 was $9,969and $_0~~securities..

Interest expense related to the margin loan was approximately $14,000 and $10,000 for the years ended March 31, 2026, and 2025, respectively.

NOTE 10 – ACQUISITION AND RELATED TRANSACTIONS

~~Mister~~On ~~Meds~~April ~~was acquired for a total consideration of $54,220 on October~~ 1, ~~2024~~2025, ~~and~~the ~~Avenvi,~~Company ~~LLC was~~ acquired ~~for~~100% ~~total consideration~~ of ~~$1,058,788 and~~ the ~~assumption~~outstanding equity interests of aLas ~~$400,000~~Villas ~~short-term~~Health ~~loan~~Care, ~~which~~LLC ~~was~~(“Las ~~fully~~Villas”) and ~~paid before March 31~~DOCConsultations, ~~2025.~~LLC ~~The~~(“DOCConsultations”) ~~Company~~for ~~followed~~total ~~the~~cash ~~guidelines~~consideration ~~under ASC~~of ~~805~~$200, ~~Business Combinations~~000. The ~~transaction~~transactions ~~was~~were accounted for as anbusiness ~~asset~~combinations ~~acquisition.~~in Noaccordance ~~goodwill~~with ~~was~~ASC ~~recognized~~805. ~~from~~The ~~the~~ transactions ~~since~~ ~~the~~resulted ~~fair~~in ~~value of~~ the ~~assets~~recognition ~~was~~of ~~the~~goodwill ~~purchase~~of ~~price for both entities~~$117,694.

~~Mister~~On ~~Meds~~April ~~was~~1, in2025, the ~~construction~~Company ~~process~~also atacquired ~~the~~an ~~end~~80% ofcontrolling ~~March~~interest ~~31,~~in ~~2025.~~MagneChef ~~The~~through ~~company~~the isacquisition ~~projected~~of toMagnefuse ~~begin~~LLC ~~operations~~and ~~in the second quarter~~Alicat, ofLLC ~~2025.~~for ~~The~~total ~~pharmacy~~cash ~~will~~consideration ~~feature a state-~~of~~-the-art~~ ~~sterile room~~$240,500. ~~equipped~~This ~~with~~transaction ~~both~~was ~~positive~~also ~~and~~accounted ~~negative~~for ~~pressure capabilities,~~ as ~~well~~ asa ~~hazardous~~business ~~compounding~~combination ~~facilities.~~in Itaccordance ~~will~~with ~~operate from a 5,000 sq~~ASC 805. ~~ft.~~The ~~facility~~acquisition ~~owned~~resulted byin ~~Avenvi~~the ~~LLC,~~recognition aof ~~related~~goodwill ~~party.~~of ~~Additionally~~$234, ~~Mister~~068 ~~Meds~~and ~~plans~~a tononcontrolling ~~apply~~interest ~~for~~of ~~state licenses in markets where RxCompoundStore~~$60,126.~~com is not yet licensed.~~

~~Assets acquired from Avenvi LLC and Mister Meds.~~F-15

~~SCHEDULE~~The OFfollowing ~~ASSETS~~table ~~ACQUIRED~~summarizes ~~CONSIDERATION~~the ~~BETWEEN~~preliminary ~~THE~~allocation ~~TWO~~of ~~ENTITIES~~the aggregate purchase price to the estimated fair value of the assets acquired and liabilities assumed:

Cash	$	295,760
Investments		186,824
Property and equipment		600,951
Intangibles assets		29,473
Total assets acquired	$	1,113,008
Purchase price	$	1,113,008

Assets and Liabilities acquired from Villas, DOC, Magnefuse, LLC. and Alicat, LLC, are as follows:


Cash	$	32,434
Inventory		36,605
Property and equipment		71,682
Intangibles assets		72,842
Total assets acquired		213,563
Accounts payable		(64,699	)
Net Assets		148,864
Aggregate purchase consideration and noncontrolling interest		500,626
Goodwill	$	351,762

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired and is primarily attributable to expected synergies, workforce in place, and future economic benefits arising from the acquisitions.

NOTE 11 – COMMITMENTS AND CONTINGENCIES

Commitments and contingencies

The Company accounts for contingencies in accordance with ASC 450, Contingencies. A liability is recorded when it is probable that a loss has been incurred, and the amount can be reasonably estimated. If a loss is reasonably possible but not probable, or if the amount cannot be estimated, the nature of the contingency and an estimate of the possible loss, if determinable, is disclosed. Remote contingencies are generally not disclosed unless related to guarantees.

F-16

Legal Matters:

From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. As of March 31, ~~2025~~2026, there were no pending or threatened legal actions that, in management’s opinion, are expected to have a material adverse effect on the Company’s financial position, results of operations, or cash flows.

~~Employment~~Derivatives and ~~Consulting~~Short ~~Agreements~~Positions:

OnFrom ~~December~~time ~~30,~~to ~~2024~~time, the Company ~~adopted~~sells acall ~~new~~options ~~compensatory~~against ~~arrangement for~~ its ~~executive~~investments ~~officers,~~in ~~which~~publicly ~~superseded~~traded ~~the~~equity ~~prior~~securities ~~plan. Under this arrangement, Giorgio R. Saumat, the Company’s CEO~~ and ~~Chairman~~maintains ofshort ~~the Board, shall receive a monthly salary of $200,000.00~~positions ~~during~~in ~~the~~publicly ~~term~~traded ofequity ~~this agreement~~securities. InThe ~~addition~~open toderivative ~~the~~contracts ~~monthly salary~~ and inshort ~~lieu~~positions of stock compensation (which the Company does not offer) the Executive is entitled to quarterly performance bonuses equal to 10% of the Company’s revenue for the preceding quarter. These bonuses are contingent on ~~the~~March ~~Company’s assets increasing quarter over quarter by at least 5% . Mario G. Tabraue~~31, ~~the Company’s COO and a member of the Board of Directors~~2026, ~~shall~~were ~~receive a monthly salary of $150,000.00 during the term of this agreement. In addition to the monthly salary and in lieu of stock compensation (which the Company does~~ not ~~offer)~~material ~~the Executive is entitled~~ to ~~quarterly performance bonuses equal to 7%of~~ the ~~Company’s revenue for the preceding quarter. These bonuses are contingent on the Company’s assets~~consolidated ~~increasing~~financial ~~quarter by at least 5%~~statements. ~~These arrangements are for 24 months beginning on January 1, 2025.~~

F-16

NOTE 12 – EQUITY

Preferred stock:

Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of March 31, 2026, and March 31, 2025, respectively.

The Company is authorized to issue 1,000,000 shares of Series B Preferred Stock, par value $0.001 per share. As of March 31, 2026, 1,000,000 shares of Series B Preferred Stock were issued and outstanding.

The Series B Preferred Stock has a stated value of $0.001 per share and is not entitled to receive dividends. Holders of the Series B Preferred Stock have no conversion or exchange rights.

In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, the Series B Preferred Stock is entitled to receive payment or distribution of a preferential amount prior to any payments or distributions to holders of common stock or other classes or series of capital stock, unless such class or series is expressly designated as senior to the Series B Preferred Stock. The Series B Preferred Stock ranks senior to the Company’s common stock with respect to distributions upon liquidation and dissolution.

The holders of the Series B Preferred Stock vote together with the holders of the Company’s common stock and any other voting class of preferred stock as a single class on all matters submitted to shareholders, including the election of directors. Pursuant to the Certificate of Designation, the aggregate voting power of the outstanding Series B Preferred Stock equals 150% of the aggregate voting power of the Company’s outstanding common stock and any other voting preferred stock, excluding the Series B Preferred Stock. As a result, the holder of the Series B Preferred Stock possesses voting control over matters submitted to shareholders for approval.

The rights, preferences, and privileges of the Series B Preferred Stock may not be adversely altered without the written consent of a majority of the holders of the Series B Preferred Stock.

The Certificate of Designation further provides that if a holder of Series B Preferred Stock ceases to serve as an officer or director of the Company for any reason, all shares of Series B Preferred Stock held by such individual shall be automatically cancelled.

As of March 31, 2026, all outstanding shares of Series B Preferred Stock were held by the Company’s Chief Executive Officer. Accordingly, the Chief Executive Officer possesses voting control over matters submitted to shareholders, including the election of directors and the approval of significant corporate transactions.

Common stock:

The Company ~~has~~is authorized ~~350~~to issue 300,000,000 shares of ~~$.001~~common stock, par value ~~common~~$0.001 ~~stock~~per share. As of March 31, ~~2025~~2026, the Company had 291,324,607 shares of common stock issued and outstanding. As of March 31, ~~2024~~2025, the Company ~~had~~and 295,347,903 ~~and~~ ~~309,981,819~~ shares, ~~respectively,~~ of common stock issued and 294,302,607 ~~and~~ ~~309,981,819~~ shares outstanding.

~~During the fiscal year ended March 31, 2025, the Company did not issue any stock.~~F-17

During the fiscal year ended March 31, 2026, the Company repurchased shares of its common stock for an aggregate purchase price of $471,410 pursuant to an authorized share repurchase program. A total of 4,023,296 shares were retired, and no shares were held as treasury stock as of March 31, 2026.

During the Fiscal Year ended March 31, 2025, the Company repurchased $1,465,425 of its common stock, 14,633,916 shares were cancelled, and 1,045,296 were held in treasury as of March 31, 2025.

NOTE 13 – RELATED PARTY TRANSACTIONS

The Company ~~follows~~pays ~~the~~compensation ~~guidance~~for ofservice ~~ASC~~provided ~~850,~~by ~~Related~~two ~~Party~~officers ~~Disclosures,~~to inthe ~~identifying~~officers’ ~~and~~solely ~~disclosing~~owned ~~transactions~~LLCs, ~~with~~Point96 ~~related~~Consulting, ~~parties~~LLC and Tabraue Consulting, LLC.

~~Parties~~The ~~are~~Company ~~considered~~leases tooffice bespace ~~related~~under ifa ~~one~~short-term ~~party~~operating ~~has~~lease from an office of the ~~ability~~Company tofrom ~~control~~Zoolzy, orLLC, ~~exercise~~an ~~significant~~entity ~~influence~~controlled ~~over~~by an officer of the ~~other~~Company, ~~party~~under ina ~~making financial~~sub-lease agreement. Lease payments of $64,094 and ~~operating~~$0 ~~decisions.~~were ~~Transactions~~made ~~with~~during ~~related~~the ~~parties~~years ~~have~~ended ~~been~~March ~~disclosed~~31, in2026, and ~~debt~~March 31, ~~acquisition~~2025, respectively and ~~officer’s~~are ~~compensation notes~~included in selling, general and administrative expenses on the accompanying statements of income.

The Company pays compensation for Giorgio R. Saumat and Mario Tabraue to their respective solely owned LLCs, Point96 Consulting, LLC and Tabraue Consulting, LLC. These entities are considered related parties under ASC 850 due to their ownership and control relationships with the individuals providing services to the Company.

On October 1, 2024, the Company completed the acquisition of Avenvi, a Florida limited liability company, for $1,058,700. The payment structure included an upfront payment of $258,780 at closing, followed by subsequent monthly payments of $200,000, which were paid over four months through January 2025. The acquisition encompasses approximately four acres of vacant residential real estate intended for development, one commercial property comprising nearly half an acre featuring a standalone building with 25,000 square feet, and cash or cash equivalents held by Avenvi. Giorgio R. Saumat, who currently serves as the Company’s CEO and the Chairman of Board, is the seller in this transaction. The transaction was reviewed and approved by the Board of Directors to ensure that the terms were no less favorable to the Company than those that could be obtained from unaffiliated third parties.

F-17

On October 1, 2024, the Company completed the acquisition of Mister Meds, a Texas limited liability company, for $54,200. Mario G. Tabraue, who currently serves as the Company’s COO and is a Director of the Board, is the seller in this transaction. The transaction was reviewed and approved by the Board of Directors to ensure that the terms were no less favorable to the Company than those that could be obtained from unaffiliated third parties.

NOTE 14 – INCOME TAXES

The components of the provision for income taxes for the years ended March 31, ~~2025~~2026, and ~~2024~~2025 are as follows:

Components of Provision for Income Taxes	~~2025~~2026			~~2024~~2025
Current
Federal	$	85246,~~581~~867		$	785,~~830~~581
State		3113,~~195~~753			531,~~173~~195
Total Current Provision		~~116~~260,~~776~~620			13116,~~003~~776
Deferred
Federal		~~(458~~1,~~686~~297,697	)		(~~203~~458,~~122~~686	)
State		(~~120~~25,~~132~~185	)		(53120,~~199~~132	)
Total Deferred Provision (Benefit)		~~(578~~1,~~818~~272,512	)		(~~256~~578,~~321~~818	)
Change in Valuation allowance		~~578~~(2,~~818~~044,808	)		~~256~~578,~~321~~818
Total provision for Income Taxes	$	~~116~~-511,~~776~~676		$	13116,~~003~~776

The components of deferred tax assets and liabilities on March 31, ~~2025~~2026, and ~~2024~~2025, are approximately as follows:

	2025			2024
	2026			2025
	Year ending March, 31
	2025			2024
	2026			2025
Deferred Tax assets:
Net Operating loss carry forwards	$	1804,~~446,256~~528		$	1,~~234~~446,~~852~~256
Goodwill	$	~~523,069~~0		$	~~225~~523,~~415~~069
Depreciation	$	33(133,~~700~~229	)	$	3033,~~906~~700
Other	$	66100,~~966~~995		$	-66,966
Valuation allowance	$	~~(2,069,991~~0	)	$	(12,~~491~~069,~~173~~991	)
Net deferred tax asset	$	0772,294		$	0

~~A reconciliation of the U.S. statutory federal income tax rate to the Company’s effective tax rate for the years ended March 31, 2025 and 2024 are as follows:~~F-18

A reconciliation of the U.S. statutory federal income tax rate to the Company’s effective tax rate for the years ended March 31, 2026, and 2025 are as follows:

SCHEDULE OF INCOME TAX EXPENSE RATES

	2025			2024
	2026			2025
Federal statutory income tax rate		21.0	%		21.0	%
State taxes, net of federal benefit		4.3532	%		54.535	%
Change in Valuation Allowance		(1752.1789	)%		(2417.917	)%
Net effective tax rate		8(27.1857	)%		18.618	%

ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. This first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely to be realized upon ultimate settlement. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments, and which may not accurately anticipate actual outcomes.

~~F-18~~The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of March 31, 2026, the Company has not recorded any unrecognized tax benefits.

The Company’s ~~recognizes~~policy ais ~~tax~~to ~~benefit~~record ~~from~~interest anand ~~uncertain~~penalties ~~tax~~associated ~~position~~with ~~only~~unrecognized iftax itbenefits isas ~~more~~interest ~~likely~~expense ~~than~~and ~~not~~operating expenses, ~~that~~respectively. ~~the~~As ~~tax~~of ~~position~~April ~~will~~1, ~~be sustained on examination by taxing authorities~~2024, ~~based~~the onCompany ~~the~~had ~~technical~~$0 unrecognized ~~merits~~tax ofbenefits ~~the~~and ~~position.~~$0 charges ~~The~~during ~~tax~~fiscal ~~benefits~~2026, ~~recognized~~and inaccordingly, the ~~consolidated~~Company did ~~financial~~not ~~statements~~recognize ~~from~~any ~~such~~interest aor ~~position~~penalties ~~are~~during ~~measured~~fiscal ~~based~~2026 onrelated ~~the~~to ~~largest~~unrecognized ~~benefit~~tax ~~that~~benefits. ~~has~~There awere ~~greater~~no ~~than~~material ~~50%~~accruals ~~likelihood of being realized~~for ~~upon~~uncertain ~~ultimate~~tax ~~settlement.~~positions Asas of March 31, ~~2025, the Company has not recorded any unrecognized tax benefits~~2026.

~~The~~As ~~Company’s~~of ~~policy~~March is31, to2026, ~~record~~the ~~interest~~Company ~~and~~had ~~penalties~~a ~~associated~~net ~~with~~operating ~~unrecognized~~loss ~~tax~~carry ~~benefits~~forward as(“NOL”) ~~interest~~for ~~expense~~federal and ~~operating expenses,~~state ~~respectively.~~income Astax purposes of approximately ~~April 1~~$3, ~~2024~~800,000. ~~the~~A ~~Company~~majority ~~had~~of ~~$0 unrecognized~~this ~~tax~~amount ~~benefits~~is ~~and~~from ~~$0 charges~~pre-2018. ~~during~~NOLs ~~fiscal~~generated ~~2025, and~~pre-2018 ~~accordingly,~~can ~~the~~be ~~Company~~carried ~~did~~forward ~~not~~for ~~recognize~~20 ~~any~~years ~~interest~~and post-2018 orNOLs ~~penalties~~do ~~during~~not ~~fiscal~~expire ~~2025~~but ~~related~~are limited to ~~unrecognized~~offset ~~tax~~up ~~benefits.~~to ~~There is~~80% ~~$0 accrual~~of ~~for~~taxable ~~uncertain~~income ~~tax~~in ~~positions~~any asfuture ~~of March 31, 2025~~period.

As of March 31, 2025, the Company had a net operating loss carryforward (“NOL”) for federal and state income tax purposes of approximately $5,457,000. Of this amount, $5,336,541 is from pre-2018 and $120,459 from post 2018. NOLs generated pre-2018 can be carried forward for 20 years and post-2018 NOLs do not expire, but are limited to offset up to 80% of taxable income in any future period.

Internal Revenue Code Section 382 (“Section 382”) imposes limitations on the availability of a company’s net operating losses after certain ownership changes occur. Section 382 limitation is based upon certain conclusions pertaining to the dates of ownership changes and the value of the Company on the dates of the ownership changes. It was determined that an ownership change occurred in October 2013, and March 2014. The amount of the Company’s net operating losses incurred prior to the ownership changes is limited based on the value of the Company on the date of the ownership change. Management has not determined the amount of net operating losses generated prior to the ownership change available to offset taxable income after the ownership change.

NOTE 15 – SEGMENT REPORTING

~~The~~During the years ended March 31, 2026, and 2025 our Company ~~operates~~was operated and managed as a ~~single~~1single reportable segment,. asOur ~~the~~ Chief Operating Decision Maker (“CODM”), the Chief Executive Officer (“CEO”), evaluates ~~the~~performance ~~business~~and allocates resources on athe basis of consolidated ~~basis~~financial ~~and~~results. ~~does~~Because ~~not~~the ~~receive~~Company ~~discrete~~has a single reportable segment, all segment financial information ~~for~~required ~~multiple~~by ~~business~~ASC ~~units~~280 is already included in the consolidated financial statements.

~~Measure~~The Company is evaluating options for the reorganization of ~~Segment~~segments ~~Profit~~for orthe ~~Loss~~year ended March 31, 2027.

~~The~~NOTE ~~CODM~~16- ~~assesses~~SUBSEQUENT ~~the~~EVENTS ~~Company’s financial performance based on operating income, which aligns with the amount reported in the statement of operations.~~

~~SCHEDULE~~On OFMay ~~FINANCIAL~~1, ~~PERFORMANCE~~2026, ~~BASED~~the ONCompany ~~OPERATING~~entered ~~INCOME~~into a privately negotiated agreement to repurchase 715,000 shares of its common stock at a purchase price of $0.07 per share, for aggregate consideration of $50,050. On June 1, 2026, the Company entered into a second privately negotiated agreement to repurchase 600,000 shares of its common stock at a purchase price of $0.08 per share, for aggregate consideration of $48,000. On May 26, 2026, the Company entered into a third privately negotiated agreement to repurchase an additional 450,000 shares of its common stock at a purchase price of $0.09 per share, for aggregate consideration of $40,500. In addition, the Company repurchased and retired 1,385,392 shares of its common stock through open-market transactions at an average purchase price of approximately $0.15 per share. As a result of these transactions, the Company repurchased and retired an aggregate of 3,150,392 shares of its common stock for total consideration of approximately $346,359.

	2025			2024
Revenue	$	33,117,624		$	11,953,635
Cost of Goods Sold		8,817,488			4,125,139
Gross Profit		24,300,136			7,828,496
Expenses
Salaries Expense		14,115,643			4,358,917
Selling general and administrative expenses		4,154,838			166,976
Bank charges		1,066,577			422,970
Advertising & marketing		836,860			25,283
Legal and professional fees		305,932			1,774,182
Insurance		180,281			5,363
Depreciation and amortization		151,655			149,749
Utilities		40,392			15,368
Rent expense		—			10,797
Miscellaneous		—			6,542
Total Expenses	$	20,852,178		$	6,936,147
Other income (expense)
Dividend income		9,123			—
Interest earned		17			—
Net realized gain on sale of investments		300,162			—
Unrealized Gain (Loss) on fair value changes of investments		(365,661	)		—
Interest Expense		(21,189	)		(67,207	)
Net Income before taxes		3,370,410			825,142
Income Taxes		116,776			13,003
Net Income	$	3,253,635		$	812,139

NOTE 16 – SUBSEQUENT EVENT

On April 1st, 2025, the Company acquired 100% of Las Villas Health Care, LLC and DOConsultations, LLC, for a total consideration of $200,000 cash. The Company acquired $63,980 of furniture and fixtures from Las Villas Health Care, LLC and $10,884 from DOConsultations, LLC with the remaining consideration of $125,136 recognized as goodwill.

On April 1st, 2025, the Company acquired 80% of Magnefuse, LLC, for a total consideration of $240,500 cash. The Company acquired the following assets:

SCHEDULE OF ASSETS ACQUIRED CONSIDERATION

Asset	Amount
Cash	$	8,727
Inventory		33,396
Property and Equipment		6,161
Intangibles		58,774
Goodwill		133,442
Total		240,500

The Company evaluated the transactions and performed a significance test, the acquisitions do not meet the criteria to be considered significant.

F-19

ITEM 9A. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS & PROCEDURES

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired control objectives. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

The Company’s management, including the Chief Executive Officer and Chief Financial Officer have reviewed and evaluated the effectiveness of the Company’s design and operations of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act) as of the end of the period covered by this annual Report on Form 10-K/A. Based on that review and evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this Annual report, the Company’s disclosure controls and procedures were effective as of March 31, ~~2025~~2026.

Management’s Annual Report on Internal Control Over Financial Reporting

Our disclosure controls and procedures contain components of our internal controls over financial reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the Company’s principal executive and financial officer and effected by the Company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company.

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of the Evaluation Date. In making this assessment, the Company’s management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) Internal Control-Integrated Framework (2013). The COSO framework is based upon five integrated components of control: control environment, risk assessment, control activities, information and communications and ongoing monitoring.

25Based on an evaluation under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer, Company management has concluded that the Company’s internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act were effective as of the Evaluation Date.

Based on an evaluation under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and Chief Financial Officer, Company management has concluded that the Company’s internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act were ineffective as of the Evaluation Date based on the number of adjustments from the audit. The Company will continue to improve its internal controls, to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

ITEM 9B. OTHER INFORMATION

None

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE ~~(Restated)~~

The Company does not, at present, have any employees other than the current officers and directors. We have not entered into any employment agreements, as we currently do not have any employees other than the current officers and directors.

Directors and Executive Officers

Name	Principal Occupation	Age	Director or Officer Since
Giorgio R. Saumat	CEO & Chairman of the Board	4647	2022
Mario G. Tabraue	COO & Board of Director	4647	2021
Ernesto Flores	CFO, Board of Director, Audit & Compensation Committee member	4041	2024
Christopher Rose	Chief Technology Officer (CTO)	4748	2024
Victoria Losada	Secretary, Board of Director, & Compensation Committee member	2930	2024
Jeff P.H. Cazeau	Independent Director & Audit Committee member	5859	2023
Yovan Sanchez	Board of Director	4445	2023
Emiliano Curia	Independent Director, Audit & Compensation Committee member	4647	2023

There are no other people nominated or chosen to become directors or executive officers, nor do we have any employees other than above-mentioned officers and directors.

Our directors hold office until the next annual meeting of shareholders and the election and qualification of their successors. Directors receive two thousand dollars per Board of Directors meeting attended for serving on the Board of Directors, in addition to the reimbursement of reasonable expenses incurred in attending meetings if any. Officers are appointed by the board of directors and serve at the discretion of the board.

Officer and Director Background:

Giorgio R. Saumat -CEO, Director, & Chairman

Mr. Saumat is an investor and entrepreneur with over 20 years of experience investing, operating, and consulting for private businesses ~~and~~ and investors. Having graduated from Rutgers University in 2001 with an undergraduate degree in Economics and Political Science, immediately after he co-founded ~~CASAU~~ ~~Group as~~ a private equity group specializing in real estate. In 2009 he opened and invested in multiple locations of restaurants in the greater Miami Area, which he sold in 2013. He then founded POINT96 Consulting to assist private businesses and accredited investors in realizing their personal and/or organizational objectives through unique strategic planning.

Mario G. Tabraue - President & Director

Mr. Tabraue worked from 1997 until 2002 assisting with real estate transactions as well as first- and third-party insurance claims at the law firm of Moises Kaba III. During this time, he also free-lanced, creating websites and working with businesses by creating and implementing new processes in accounting and with digital technologies. From 2002 until 2009, Mr. Tabraue worked for Eller-ITO Stevedoring Company at the Port of Miami where he served in operations and logistics, first with simple vessel operations, and, as he demonstrated his skills, advanced to complex operations and finally management of full vessel planning and operations. From 2009 until 2013, Mr. Tabraue worked for Ceres Marine Terminals as an operations manager, where he was given ever increasing responsibilities until, among his duties, ~~were~~he ~~negotiating~~negotiated contract issues with union labor officials and contract negotiations with companies such as Royal Caribbean, Mediterranean Shipping Lines, Hapag-Lloyd and others. In 2013 through 2014 he began working with Zoological Wildlife Foundation, a business founded by his family in 2008. At the Foundation he restructured operations, tour packages, the accounting systems, and fully automated their booking system through the company’s website. Ultimately all internal procedures were automated and made paperless. In 2014 Mr. Tabraue was recruited back to Eller-ITO where he returned as Marine Manager and has advanced to the position of Special Projects Manager. In 2019, he began work for JCR Medical Equipment, serving as the head of finance. In 2020 Mr. Tabraue purchased RxCompoundStore.com with the vision of starting a telemedicine platform to expand the company’s reach and to compete in the online market.

Jeff P.H. Cazeau - Independent Director

Mr. Cazeau is an attorney whose practice areas have included Government Contracts, Lobbying and Municipal Law. Mr. Cazeau currently serves as the City Attorney for the City of North Miami. Prior to becoming City Attorney, Mr. Cazeau assisted clients in obtaining and keeping contracts with federal, state, and local government entities. Mr. Cazeau is experienced in assisting small, minority, and women owned businesses in obtaining various socio-economic certifications such as Disadvantaged Business Enterprise (DBE); Airport Concessions Disadvantaged Business Enterprise (ACDBE) certifications and SBA 8(a). Before attending law school, Mr. Cazeau served nine years as a commissioned officer in the United States Navy. During his naval career he held several positions, including Anti-Submarine Warfare Officer, Legal Officer, and Navigator aboard USS ELLIOT (DD 967), and Politico-Military Affairs Officer at United States Southern Command (SOUTHCOM).

Ernesto Flores - CFO

Mr. Flores is an accomplished financial professional with over a decade of experience and a strong educational background. He holds a Bachelor of Science degree in Accounting from Florida National University and a Master of Science degree in Taxation from Nova Southeastern University. Throughout his career, Mr. Flores has held significant roles in both large corporations and mid-sized organizations, demonstrating adaptability and leadership. At St. George Logistics, he served as Divisional Controller, overseeing financial operations and ensuring regulatory compliance. His four-year tenure at Curated Investments, LLC as Financial Controller highlighted his ability to manage financial functions effectively and drive strategic initiatives. Mr. Flores possesses a diverse skill set, including preparing companies for growth, implementing systems integration, maintaining controllership, managing risk, optimizing inventory control, overseeing P&L management, establishing internal controls, facilitating financial reporting, conducting audits, and driving process improvements.

Christopher Rose CTO

Chris Rose is a dynamic and innovative leader with a diverse background in technology, entrepreneurship, and strategic leadership. In his former leadership role at a Fortune 100 company, Chris established and managed an enterprise-wide automation factory. That factory, comprised of a diverse team across the US, UK, and India, achieved significant milestones, including twenty million dollars in annual transactional cost reduction and the automation of over hundreds business processes.

Chris has always had an entrepreneurial spirit. He brings his passion for, and successful experience with, leading startups to ETST, where he employs technology to achieve tangible business outcomes, predominantly driving operational efficiency and cost savings.

Chris is known for his hands-on approach, collaborative leadership style, and commitment to developing high-performing teams. A Miami native, Chris is also an adventurer who enjoys freediving, spearfishing, and boating, and who carries with him an unwavering optimism. With twenty plus years of technology leadership and exploration behind him, he is uniquely poised to make a significant impact as ETST’s Chief Technology Officer.

Victoria Losada -Secretary & Director

Victoria Losada has been working in healthcare since 2018. She is a dedicated professional and has been leveraging her extensive experience and expertise to enhance the operations and efficiency at RxCompoundStore.com, LLC. since August of 2022. In 2023, Victoria was selected as Secretary and Treasurer of Earth Science Tech. She brought her practical insights and leadership experience to help guide the strategic direction and governance of the company. Her diverse professional background and commitment to excellence make her a valued asset in shaping innovative solutions and policies within Earth Science Tech as well as all its current and future subsidiaries.

Yovan Sanchez - Director

Mr. Sanchez is a seasoned firefighter/paramedic and a driven entrepreneur. With more than two decades of dedicated service in the firefighting and paramedic field, he has been a stalwart in his community. In addition to his public service, Yovan is also a real estate owner and manager in South Florida. In 2011, he took the initiative to establish Hot Box Incubators Corp. Yovan’s commitment to community development extends to supporting youth programs, culminating in the creation of Miami Springs Jiu Jitsu in 2022. Furthermore, he possesses over 20 years of valuable experience in the boat and yacht industry, specializing in identifying opportunities and harnessing them to his advantage. His extensive network of connections across various industries bolsters his ability to make the most of these opportunities.

Emiliano Curia- Director

Dr. Curia is a physical medicine and rehabilitation physician with expertise in musculoskeletal disorders and neurorehabilitation after injuries or illness. He completed his residency at Jackson Memorial Hospital and Larkin Community Hospital, where he also served as Chief Resident. Prior to residency he served as medical research director for multiple pharmaceutical clinical trials and orthopedic technology development and implementation. He participated in multiple community outreach programs and developed quality improvement protocols for underserved populations in Miami Dade county. Dr Curia currently treats patients with musculoskeletal disorders, athletes, and amputees.

Committees of The Board of Directors

The Company is managed under the direction of Giorgio R. Saumat, Mario G. Tabraue, Jeff P.H. Cazeau, Yovan Sanchez, Emiliano Curia, Ernesto Flores, and Victoria Losada.

The Company’s Audit Committee and Compensation Committee each consist of three members of the Board of Directors, two of whom are independent directors.

Officer’s and Director’s Involvement in Legal Proceedings

No executive Officer or Director of the Company has been convicted of any criminal proceeding (excluding traffic violations) or is the subject of a criminal proceeding that is currently pending. No executive Officer or Director of the Company is the subject of any pending legal proceedings. No Executive Officer or Director of the Company is involved in any bankruptcy petition by or against any business in which they are a general partner or executive officer currently or within two years of any involvement as a general partner, executive officer, or Director of any business.

ITEM 11. EXECUTIVE COMPENSATION

On September 29, 2023, the Company adopted a new compensatory arrangement for its executive officers, which superseded the prior plan. Under this arrangement, Giorgio R. Saumat, the Company’s CEO and Chairman of the Board, was entitled to receive twenty-one percent of the Company’s monthly revenue. Mario G. Tabraue, the Company’s COO and a member of the Board of Directors, was entitled to receive ten and one-half percent of the Company’s monthly revenue. This arrangement commenced on October 1, 2023, for a twelve-month term. Compensation was payable on the first day of each month based on the revenue generated in the preceding month, provided the Company increased its cash position on a quarter-over-quarter basis. In the event the Company failed to increase its cash position in a given quarter, the arrangement was subject to renegotiation, and no payments would be made at the beginning of the subsequent quarter. On August 15, 2024, the Board of Directors approved new twelve-month employment agreements for both the CEO and the COO, effective October 1, 2024. Pursuant to these agreements, the CEO was entitled to receive eighteen percent of the Company’s monthly cash receipts, while the COO was entitled to receive twelve percent. As with the prior arrangement, payments were contingent upon the Company achieving a quarter-over-quarter increase in net profit. If net profit did not increase for a given quarter, the agreements would require renegotiation, and no payments would be made at the beginning of the following quarter. On December 30, 2024, the CEO and COO entered into an amendment to their respective employment agreements, which was approved by the Board of Directors and became effective January 1, 2025. Under the amended terms, the CEO receives a fixed monthly salary of two hundred thousand dollars, and the COO receives a fixed monthly salary of one hundred fifty thousand dollars. In addition to their base salaries, and in lieu of any stock-based compensation, both officers are eligible to receive quarterly performance bonuses, provided the Company’s total assets increase by at least five percent on a quarter-over-quarter basis. If this performance threshold is met, the CEO is entitled to a bonus equal to ten percent of the Company’s revenue for the preceding quarter, and the COO is entitled to a bonus equal to seven percent of the Company’s revenue for the same period. ~~Additionally,~~In a inmove ~~their~~to ~~capacities~~maximize asthe ~~members~~Company’s ofoperating leverage and demonstrate fiscal discipline, the ~~Board~~CEO ofand ~~Directors~~COO mutually agreed to rescind these Amended Employment Agreements on February 15, 2026, the CEO and COO ~~are~~mutually ~~entitled~~agreed to ~~receive~~rescind ~~four~~their ~~thousand~~prior ~~dollars~~Amended ~~for~~Employment ~~each~~Agreements dated December 30, 2024. Both executives have waived all revenue-based bonuses and variable compensation during this interim period. Their employment remains at-will and at the pleasure of the Board of Directors, and the interim terms will continue until after the Company’s ~~meeting~~July ~~attended~~2026 Annual Meeting of Shareholders.

On March 414, 2024, the Company’s Board of Directors appointed Ernesto L. Flores as Chief Financial Officer, succeeding Gabrielle Schuster. Mr. Flores receives an annual base salary of one hundred sixty thousand dollars, paid on a biweekly basis. He is eligible for milestone-based bonuses, as well as a year-end discretionary bonus determined by the Company’s Chief Executive Officer. On December 26, 2024, Mr. Flores was elected to the Company’s Board of Directors and appointed as a member of the Audit and Compensation Committees. In this capacity, he is entitled to receive compensation of four thousand dollars for each Board meeting attended. On March 11, 2025, the Board of Directors and the Compensation Committee approved the continuation of Mr. Flores’s compensation arrangement and added performance-based bonuses, with amounts to be determined at the sole discretion of the Chief Executive Officer. On March 11, 2026, the Company and Mr. Flores mutually agreed to renew his Employment Agreement for an additional one-year term. All other material terms and conditions of Employment Agreement remain unchanged and in full force and effect.

On April 16, 2024, the Company’s Board of Directors appointed Christopher Rose as the Company’s Chief Technology Officer (“CTO”). Mr. Rose will receive an annual base salary of two hundred seventy thousand dollars, payable on a biweekly basis. In addition, he will be eligible to receive milestone-based bonuses and may be considered for a discretionary year-end bonus, as determined by the Company’s Chief Executive Officer. On March 11, 2025, the Board of Directors and the Compensation Committee approved the continuation of Mr. Rose’s compensation arrangement and added performance-based bonuses, the amounts of which will be determined at the sole discretion of the Chief Executive Officer.30

~~Victoria~~On ~~Losada~~April 16, 2024, the Company’s ~~Secretary~~Board ~~elected~~of inDirectors ~~late~~appointed ~~2023,~~Christopher ~~receives~~Rose ~~compensation~~as the Company’s Chief Technology Officer (“CTO”). Mr. Rose will receive an annual base salary of ~~five~~two hundred seventy thousand dollars, ~~for~~payable ~~each~~on ~~Board~~a ~~meeting~~biweekly ~~attended in~~basis. ~~her~~In ~~capacity~~addition, ashe ~~Secretary.~~will be Oneligible ~~December~~to ~~26,~~receive ~~2024,~~milestone-based ~~Ms.~~bonuses ~~Losada~~and ~~was~~may ~~also~~be ~~elected~~considered asfor a ~~member~~discretionary ofyear-end bonus, as determined by the Company’s Chief Executive Officer. On March 11, 2025, the Board of Directors and the Compensation Committee approved the continuation of Mr. Rose’s compensation arrangement and ~~appointed~~added asperformance-based abonuses, ~~member~~the amounts of which will be determined at the ~~Compensation~~sole ~~Committee~~discretion of the Chief Executive Officer. On March 11, ~~entitling~~2026, ~~her~~the Company and Mr. Rose mutually agreed to renew his Employment Agreement for an additional ~~four~~one-year term. ~~thousand~~All ~~dollars~~other ~~for~~material ~~each~~terms ~~Board~~and ~~meeting attended~~conditions of Employment Agreement remain unchanged and in ~~that~~full ~~role~~force and effect.

Victoria Losada, the Company’s Secretary elected in late 2023, receives compensation of five hundred dollars for each Board meeting attended in her capacity as Secretary. On December 26, 2024, Ms. Losada was also elected as a member of the Company’s Board of Directors and appointed as a member of the Compensation Committee.

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE-IN-CONTROL

SEC regulations state that we must disclose information regarding agreements, plans or arrangements that provide for payments or benefits to our executive officers in connection with any termination of employment or change in control of the Company. Such payments are set forth above in the section entitled “Executive Compensation.”

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END

None.

OPTION/SAR GRANTS IN THE LAST FISCAL YEAR

None.

CONSULTING AGREEMENTS WITH OFFICERS AND DIRECTORS

None.

DIRECTOR COMPENSATION

InDuring ~~2024~~the fiscal year ended March 31, 2026, the Company ~~began~~maintained ~~compensating~~its ~~each~~commitment ofto ~~its~~high-level ~~members~~corporate ofgovernance ~~the~~through its Board of Directors, which ~~four~~provides ~~thousand~~strategic ~~dollars~~oversight ~~per~~across the Company’s pharmaceutical, telemedicine, and asset management divisions. The Board’s compensation structure is designed to attract and retain qualified individuals while remaining mindful of ~~Directors~~the ~~meeting~~Company’s focus on ~~attended~~lean ~~during~~operations ~~their~~and ~~term~~disciplined capital management.

In 2024, the Company implemented a standard compensation policy for its Board of Directors, awarding four thousand dollars per meeting attended to each member. This policy applied to executive directors and independent directors alike, ensuring that those responsible for the Company’s fiduciary and strategic direction were appropriately compensated for their time and expertise.

On February 15, 2026, as part of a broader initiative to optimize corporate overhead and reallocate resources toward strategic growth, the Company and all members of its Board of Directors entered into an Omnibus Amendment to Director Agreements. This amendment uniformly modified the compensation for Board meeting attendance for the entire Board, including independent directors Jeff P.H. Cazeau and Emiliano Curia, MD.

Effective immediately upon the execution of the Omnibus Amendment, the compensation for attendance at Board meetings was reduced by fifty percent, from four thousand dollars to two thousand dollars per meeting. This adjustment reflects a unified effort by the Board to align its interests with those of the shareholders by preserving cash for operational scaling and the systematic reduction of authorized common stock.

All other substantive terms of the prior director agreements, including provisions regarding confidentiality, non-disclosure, and indemnification obligations, remain in full force and effect. The Board believes that this revised compensation structure remains sufficient to ensure the ongoing dedication and oversight of its members leading into the July 2026 Annual Meeting of Shareholders.

INDEMNIFICATION OF DIRECTORS AND OFFICERS

The Company’s officers and directors are indemnified as provided by the Florida Statutes and the Company’s bylaws.

The Company’s bylaws provide that it will advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or officer of the Company, or is or was serving at the request of Earth Science Tech as a director or executive officer of another company, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefore, all expenses incurred by any director or officer in connection with such proceeding upon receipt of an undertaking by or on behalf of such person to repay said amounts if it should be determined ultimately that such person is not entitled to be indemnified under the bylaws or otherwise.

There are no annuity, pension or retirement benefits proposed to be paid to officers, directors, or employees of the corporation in the event of retirement at normal retirement date pursuant to any presently existing plan provided or contributed to by Company.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

As of March 31, ~~2025~~2026, we had outstanding ~~295~~291,~~347~~324,~~903~~607 shares of common stock. Each share of common stock is currently entitled to one vote on all matters put to a vote of our stockholders. The following table sets forth the number of common shares, and percentage of outstanding common shares, beneficially owned as of the date hereof by:

	●	each person known by us to be the beneficial owner of more than five percent of our outstanding common stock;

	●	each of our current directors;

	●	each our current executive officers and any other persons identified as a “named executive” in the Summary Compensation Table above; and

	●	all our current executive officers and directors as a group.

3032

Beneficial ownership is determined in accordance with the rules of the SEC and includes general voting power and/or investment power with respect to securities. Shares of common stock issuable upon exercise of options or warrants that are currently exercisable or exercisable within 60 days of the record date, and shares of common stock issuable upon conversion of other securities currently convertible or convertible within 60 days, are deemed outstanding for computing the beneficial ownership percentage of the person holding such securities but are not deemed outstanding for computing the beneficial ownership percentage of any other person. Under the applicable SEC rules, each person’s beneficial ownership is calculated by dividing the total number of shares with respect to which they possess beneficial ownership by the total number of outstanding shares. In any case where an individual has beneficial ownership over securities that are not outstanding but are issuable upon the exercise of options or warrants or similar rights within the next 60 days, that same number of shares is added to the denominator in the calculation described above. Because the calculation of each person’s beneficial ownership set forth in the “Percentage Beneficially Owned” column of the table may include shares that are not presently outstanding, the total sum of the percentages set forth in such a column may exceed 100%. Unless otherwise indicated, the address of each of the following persons is 8950 SW 74^th CT Suite 1401, Miami, FL 33156, USA, and, based upon information available or furnished to us, each such person has sole voting and investment power with respect to the shares set forth opposite his, her or its name.

Beneficial Owner (1)	Common Stock		Series B Preferred Stock		Number of Shares Beneficially Owned (2)		Percent (3)
5% Stockholders:
Jose Rodriguez (4)		16,000,000				16,000,000		5.42	%
Jose Rodriguez		16,000,000				16,000,000		5.49	%
Mario A. Portela		20,500,000				20,500,000		67.9404	%
Dr. Issa El-Cheikh		23,000,000				23,000,000		7.79	%
Dr. Issa El-Cheikh (4)		16,300,000				16,300,000		5.60	%
Named Executive Officers and Directors:
Giorgio R. Saumat – CEO, Secretary and Chairman of the Board (5)		122,~~780~~930,127		1,000,000		122,~~780~~930,127		4142.5720	%
Mario G. Tabraue - COO & Board of Director (6)		12,422,023				12,422,023		4.21	%
Mario G. Tabraue - COO & Board of Director		12,422,023				12,422,023		4.26	%
Ernesto L. Flores - CFO, Board of Director, Audit and Compensation Committee member (7)		94,978				94,978		0.03	%
Ernesto L. Flores - CFO, Board of Director, Audit and Compensation Committee member		94,978				94,978		0.03	%
Christopher Rose - CTO (8)		85,151				85,151		0.03	%
Christopher Rose - CTO		85,151				85,151		0.03	%
Victoria Losada - Treasurer, Board of Director, and Compensation Committee member(9)		1,051,001				1,051,001		0.36	%
Victoria Losada - Treasurer, Board of Director, and Compensation Committee member		1,051,001				1,051,001		0.36	%
Yovan Sanchez - Board of Director (10)		1,606,151				1,606,151		0.54	%
Yovan Sanchez - Board of Director (6)		1,700,000				1,700,000		0.58	%
Jeff P.H. Cazeau - Independent Director, Audit and Compensation Committee member (11)		318,860				318,860		0.11	%
Jeff P.H. Cazeau - Independent Director, Audit and Compensation Committee member		318,860				318,860		0.11	%
Emiliano Curia, MD - Independent Director and Audit Committee member (12)		5,000				5,000		0.00	%
Emiliano Curia, MD - Independent Director and Audit Committee member		5,000				5,000		0.00	%
All executive officers and directors as a group (8 persons)						138,~~363~~607,~~291~~140		4647.8558	%

(1)	Except as otherwise indicated, the people named in this table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and to the information contained in the footnotes to this table.

3133

(2)	Under SEC rules, a person is deemed to be the beneficial owner of shares that can be acquired by such a person within 60 days upon the exercise of options or the settlement of other equity awards.
(3)	Calculated on the basis of 295,347,903 shares of common stock outstanding as of March 31, 2025, plus any additional shares of common stock that a stockholder has the right to acquire within 60 days after March 31, 2025. Further, the positions listed are as of the date of this Registration Statement.
(4)	Since the last reported fiscal year end, Jose Rodriguez sold and gifted a total of 4,500,000 shares of the Company’s common stock through private transactions.
(5)	Since the last reported fiscal year end, Giorgio R. Saumat increased his ownership position by acquiring a total of 3,077,720 shares of the Company’s common stock through open market purchases, at prices ranging from $0.0625 to $0.27 per share. All such acquisitions were disclosed by Mr. Saumat in Form 4 filings, in accordance with SEC regulations.
(6)	Since the last reported fiscal year end, Mario G. Tabraue increased his ownership position by acquiring a total of 170,000 shares of the Company’s common stock through open market purchases, at prices ranging from $0.15 to $0.249 per share. All such acquisitions were disclosed by Mr. Tabraue in Form 4 filings, in accordance with SEC regulations.
(7)	Ernesto L. Flores has served as the Company’s CFO since March 2024. During the current year-end reporting period, Mr. Flores acquired 94,978 shares of the Company’s common stock through open market purchases at prices ranging from $0.20 to $0.23 per share. All such acquisitions were disclosed by Mr. Flores in Form 4 filings, in compliance with SEC regulations.
(8)	Christopher Rose has served as the Company’s CTO since April 2024. During the current year-end reporting period, Mr. Rose acquired 85,151 shares of the Company’s common stock through open market purchases at prices ranging from $0.15 to $0.22 per share. All such acquisitions were disclosed by Mr. Rose in Form 4 filings in compliance with SEC regulations.

(2)	Under SEC rules, a person is deemed to be the beneficial owner of shares that can be acquired by such a person within 60 days upon the exercise of options or the settlement of other equity awards.

(3)	Calculated on the basis of 291,324,607 shares of common stock outstanding as of March 31, 2026, plus any additional shares of common stock that a stockholder has the right to acquire within 60 days after March 31, 2026.

(4)	Since the last reported fiscal year end, Dr. Issa El-Cheikh gifted a total of 6,700,000 shares of the Company’s common stock to a family member.

(5)	Since the last reported fiscal year end, Giorgio R. Saumat increased his ownership position by acquiring a total of 150,000 shares of the Company’s common stock through open market purchases, at prices ranging from $0.20 to $0.205 per share. All such acquisitions were disclosed by Mr. Saumat in Form 4 filings, in accordance with SEC regulations.

(6)	Since the last reported fiscal year end, Yovan Sanchez increased his ownership position by acquiring a total of 93,849 shares of the Company’s common stock through open market purchases, at prices ranging from $0.175 to $0.20 per share. All such acquisitions were disclosed by Mr. Sanchez in Form 4 filings, in accordance with SEC regulations.

(9)	Victoria Losada has served as the Company’s Secretary since late 2023. In early 2023, Ms. Losada privately purchased 1,000,001 shares of the Company’s common stock directly from the Company. During the current year-end reporting period, she acquired an additional 51,000 shares of common stock through open market purchases at prices ranging from $0.20 to $0.23 per share. All such acquisitions were disclosed by Ms. Losada in Form 4 filings, in compliance with SEC regulations.
(10)	Since the last reported fiscal year end, Yovan Sanchez increased his ownership position by acquiring a total of 956,151 shares of the Company’s common stock through open market purchases, at prices ranging from $0.059 to $0.18 per share. All such acquisitions were disclosed by Mr. Sanchez in Form 4 filings, in accordance with SEC regulations.
(11)	Jeff P.H. Cazeau has served as the Independent Director since February 2023. During the current year-end reporting period, Mr. Cazeau acquired 318,860 shares of the Company’s common stock through open market purchases at prices ranging from $0.12 to $0.22 per share. All such acquisitions were disclosed by Mr. Cazeau in Form 4 filings in compliance with SEC regulations.
(12)	Emiliano Curia MD has served as the Company’s Independent Director since late 2023. During the current year-end reporting period, Mr. Curia acquired 5,000 shares of the Company’s common stock through open market purchases at $0.18 per share. His acquisition was disclosed by Mr. Curia in a Form 3 filing in compliance with SEC regulations.

Rule 13d-3 under the Securities Exchange Act of 1934 governs the determination of beneficial ownership of securities. That rule provides that a beneficial owner of a security includes any person who directly or indirectly has or shares voting power and/or investment power with respect to such security. Rule 13d-3 also provides that a beneficial owner of a security includes any person who has the right to acquire beneficial ownership of such security within sixty days, including through the exercise of any option, warrant or conversion of a security. Any securities not outstanding which are subject to such options, warrants or conversion privileges are deemed to be outstanding for the purpose of computing the percentage of outstanding securities of the class owned by such person. Those securities are not deemed to be outstanding for the purpose of computing the percentage of the class owned by any other person.

There were no grants of stock options since inception to March 31, ~~2025~~2026. We do not have any long-term incentive plans that provide compensation intended to serve as an incentive for performance.

The Board of Directors of the Company has not adopted a stock option plan. The company has no plans to adopt one but may choose to do so in the future. If such a plan is adopted, this may be administered by the board, or a committee appointed by the board (the “Committee”). The Committee would have the power to modify, extend, or renew outstanding options and to authorize the grant of new options in substitution therefor, provided that any such action may not impair any rights under any option previously granted. The Company may develop an incentive-based stock option plan for its officers and directors and may reserve up to 10% of its outstanding shares of common stock for that purpose.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

None.

EQUITY ISSUANCES TO OFFICERS AND DIRECTORS

None.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

During the fiscal year ended March 31, ~~2025~~2026, we incurred approximately $6050,000 in audit and audit related fees to our principal independent accountants for professional services rendered in connection with the audit of financial statements for the year ended March 31, ~~2025~~2026.

~~Stephano~~Semple, ~~Slack~~Marchal & Cooper, ~~LLC~~LLP is the Company’s principal auditing firm for the fiscal year ending March 31, ~~2025~~2026, which billed the Company $6050,000 for audit services during the year. The Company’s Board of Directors has considered whether the provisions of audit services are compatible with maintaining ~~Assurance~~Stephano ~~Dimensions~~Slack LLC’ independence. The engagement of our independent registered public ~~accounting~~ accounting firm was approved by our Board of Directors prior to the start of the audit of our consolidated financial statements for the year ended March 31, ~~2025~~2026.

~~Assurance~~Stephano ~~Dimensions~~Slack ~~Certified~~LLC ~~Public Accountants & Associates~~ was the audit firm that performed audit services for the fiscal year ended March 31, ~~2024~~2025.

The following table represents aggregate fees billed to the Company for the Fiscal Years ended March 31, ~~2025~~2026, and ~~2024~~2025.

Services	~~2025~~2026		~~2024~~2025
Audit fees	$	6050,000	$	6560,000
Audit related fees		-		-
Tax fees		~~7,500~~-		7,500
All other fees		-		-
Total fees	$	6750,~~500~~000	$	7267,500

3435

PART IV

ITEM 15. EXHIBITS

The following exhibits are incorporated into this Form 10-K Annual Report:

Exhibit		Incorporated by Reference		Filed or Furnished
		Incorporated by Reference		Filed or Furnished
Number	Exhibit Description	Form	Exhibit	Filing Date	Herewith
Exhibit Number	Exhibit Description	Form	Exhibit	Filing Date	Herewith
31.1	Certification of Chief Executive Officer Pursuant to Exchange Act Rule 13a-14(a) As adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X
31.2	Certification of Chief Executive Officer Pursuant to Exchange Act Rule 13a-14(a) As adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002				X
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002				X
32.2	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002				X
101.INS	Inline XBRL Instance Document				X
101.SCH	Inline XBRL Taxonomy Extension Schema				X
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase				X
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase				X
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase				X
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase				X
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)				X

ITEM 16. FORM 10-K SUMMARY

None.

3536

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EARTH SCIENCE TECH, INC.
Dated: June 26, 2025	By:	/s/ Giorgio R. Saumat
Dated: June 18, 2026	By:	/s/ Giorgio R. Saumat
		Giorgio R. Saumat
	Its:	CEO and Director

3637

Filing Compare · Earth Science Tech, Inc.